Company	ISIN	Country of Origin	Meeting Type	Meeting Date	Proposal Proposal Text Label	Vote Decision	For Or Agains Mgmt	t Issue Code Category	Pilier ESG
Pilier Social									
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	6. Shareholder Proposal Regarding Report on Access to COVID-19 Products	Against	For	SHP: Social	Pilier Social
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	8. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	7. Shareholder Proposal Regarding Intellectual Property	Against	For	SHP: Social	Pilier Social
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	8. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	9. Shareholder Proposal Regarding Report on Political Expenditures and Values Congruency	Against	For	SHP: Social	Pilier Social
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	7. Shareholder Proposal Regarding Lobbying Report	For	Against	SHP: Social	Pilier Social
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	6. Shareholder Proposal Regarding Non-Discrimination Audit	Against	For	SHP: Social	Pilier Social
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	8. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Moderna Inc	US60770K1079	US	Annual	03/05/2023	4. Shareholder Proposal Regarding Intellectual Property	Against	For	SHP: Social	Pilier Social
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	6. Shareholder Proposal Regarding Report on Political Expenditures and Values Congruency	Against	For	SHP: Social	Pilier Social
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	7. Shareholder Proposal Regarding Lobbying Report	Against	For	SHP: Social	Pilier Social
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	8. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	5. Shareholder Proposal Regarding Report on Corporate Operations with China	Against	For	SHP: Social	Pilier Social
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	6. Shareholder Proposal Regarding Report on Access to COVID-19 Products	Against	For	SHP: Social	Pilier Social
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	7. Shareholder Proposal Regarding Third-Party Political Expenditures Reporting	Against	For	SHP: Social	Pilier Social
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	8. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	9. Shareholder Proposal Regarding Congruency Report of Partnerships with Certain Organizations	Against	For	SHP: Social	Pilier Social
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	5. Shareholder Proposal Regarding Extended Patent Exclusivities and Application for Secondary and Tertiary Patents	Against	For	SHP: Social	Pilier Social
Pilier Gouvernance	_			, , , , , , , , , , , , , , , , , , , ,					
Novartis AG	CH0012005267	CH	Annual	07/03/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	2 Ratification of Board and Management Acts	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	4 Cancellation of Shares and Reduction in Share Capital	For	For	Capital Management	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	5 Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	6.1 Amendments to Articles (Virtual General Meetings)	For	For	Changes to Company Statutes	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	6.2 Amendments to Articles (Miscellaneous)	For	For	Changes to Company Statutes	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	6.3 Amendments to Articles (Alignment with Law)	For	For	Changes to Company Statutes	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	7.1 Board Compensation	For	For	Compensation	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	7.2 Executive Compensation	For	For	Compensation	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	7.3 Compensation Report	For	For	Compensation	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.1 Elect Jörg Reinhardt as Board Chair	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.2 Elect Nancy C. Andrews	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.3 Elect Ton Büchner	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.4 Elect Patrice Bula	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.5 Elect Elizabeth Doherty	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.6 Elect Bridgette P. Heller	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.7 Elect Daniel Hochstrasser	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.8 Elect Frans van Houten	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.9 Elect Simon Moroney	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.10 Elect Ana de Pro Gonzalo	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	СН	Annual	07/03/2023	8.11 Elect Charles L. Sawyers	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	8.12 Elect William T. Winters	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	СН	Annual	07/03/2023	8.13 Elect John D. Young	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	9.1 Elect Patrice Bula as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	СН	Annual	07/03/2023	9.2 Elect Bridgette P. Heller as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	9.3 Elect Simon Moroney as Compensation Committee Chair	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	9.4 Elect William T. Winters as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	10 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Annual	07/03/2023	11 Appointment of Independent Proxy	For	For	Meeting Administration	Pilier Gouvernance
Novartis AG	CH0012005267	СН	Annual	07/03/2023	B Transaction of Other Business	Against		Meeting Administration	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	2 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	4 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	5 Directors' Fees	For	For	Compensation	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	6.A Elect Niels Bjørn Christiansen	Abstain	Against	Board Related	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	6.B Elect Niels Jacobsen	For	For	Board Related	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	6.C Elect Anja Madsen	Abstain	Against	Board Related	Pilier Gouvernance
		DK	Annual	08/03/2023	6.D Elect Sisse Fjelsted Rasmussen	Abstain	Against	Board Related	Pilier Gouvernance

Demant AS	DK0060738599	DK	Annual	08/03/2023	6.E Elect Kristian Villumsen	For	For	Board Related	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	7 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	8.A Authority to reduce share capital	For	For	Capital Management	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	8.B Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Demant AS	DK0060738599	DK	Annual	08/03/2023	8.C Authorization of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	2 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	4 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	5.1 Directors' Fees 2022	For	For	Compensation	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	5.2 Directors' Fees 2023	For	For	Compensation	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	5.3 Amendments to Remuneration Policy	For	For	Compensation	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.1 Elect Helge Lund as Chair	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.2 Elect Henrik Poulsen as Vice Chair	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.A Elect Laurence Debroux	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.B Elect Andreas Fibig	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.C Elect Sylvie Grégoire	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.D Elect Kasim Kutay	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.E Elect Christina Choi Lai Law	For	For	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	6.3.F Elect Martin Mackay	Abstain	Against	Board Related	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	7.1 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	8.1 Cancellation of Shares	For	For	Capital Management	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	8.2 Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	8.3 Authority to Issue Shares w/ or w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Novo Nordisk	DK0060534915	DK	Annual	23/03/2023	8.4 Shareholder Proposal Regarding Company's Product pricing	Against	For	SHP: Governance	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	2 Consolidated Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
		FR			·			·	
Sartorius Stedim Biotech S.A.	FR0013154002		Mix	27/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	4 Special Auditors Report on Regulated Agreements	Against	Against	Board Related	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	5 2023 Remuneration Policy (Board of Directors)	For	For	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	6 2022 Remuneration Report	Against	Against	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	7 2022 Remuneration of Joachim Kreuzburg, Chair and CEO	Against	Against	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	8 2023 Remuneration Policy (Chair and CEO)	For	For	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	9 2022 Remuneration of René Faber, Deputy CEO	Against	Against	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	10 2023 Remuneration Policy (Deputy CEO)	For	For	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	11 Authority to Repurchase and Reissue Shares	For	For	Capital Management	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	12 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	13 Authority to Issue Shares w/o Preemptive Rights (Unicorn-Biotech Holding GmbH & META Ingenium)	For	For	Capital Management	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	14 Authority to Cancel Shares and Reduce Capital	For	For	Capital Management	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	15 Employee Stock Purchase Plan	Against	Against	Compensation	Pilier Gouvernance
Sartorius Stedim Biotech S.A.	FR0013154002	FR	Mix	27/03/2023	16 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	4 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.A Elect Deirdre P. Connelly	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.B Elect Pernille Erenbjerg	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.C Elect Rolf Hoffman	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.D Elect Elizabeth O'Farrell	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.E Elect Paolo Paoletti	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	5.F Elect Anders Gersel Pedersen	For	For	Board Related	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	6 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	7.A Directors' Fees	For	For	Compensation	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	7.B Amendment to Remuneration Policy (Removal of Nominal Cap)	For	For	Compensation	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	7.C Amendments to Remuneration Policy (Other Changes)	For	For	Compensation	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	7.D Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Genmab	DK0010272202	DK	Annual	29/03/2023	8 Authorization of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	2 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	4 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	5 Ratification of Board and Management Acts	For	For	Board Related	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	6.01 Elect Anders Gersel Pedersen	For	For	Board Related	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	6.02 Elect Peter Kürstein	For	For	Board Related	Pilier Gouvernance
,	DK0015998017	DK	Annual	30/03/2023	6.03 Elect Frank Verwiel	For	For	Board Related	Pilier Gouvernance
Bayarian Nordic A/S		UN	Aimaai	30/03/2023	olos Licat Frank Fermier	101	. 51	Dog. a Melatea	. mer douvernance
Bavarian Nordic A/S Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	6.04 Elect Anne Louise Eberhard	For	For	Board Related	Pilier Gouvernance

Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	6.06 Elect Heidi Hunter	For	For	Board Related	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	6.07 Elect Johan Van Hoof	For	For	Board Related	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	7.01 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8A Authority to Issue Shares w/ or w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8B Authority to Issue Convertible Debt Instruments	Against	Against	Capital Management	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8C Issuance of Warrants w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8D Amendments to Remuneration Policy	For	For	Compensation	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8E Directors' Fees	Against	Against	Compensation	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8F Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Bavarian Nordic A/S	DK0015998017	DK	Annual	30/03/2023	8G Amendments to Articles	For	For	Changes to Company Statutes	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	2.c Remuneration Report Excluding Pre-Merger Legacy Matters	Against	Against	Compensation	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	2.d Remuneration Report (Pre-Merger Legacy Matter)	Against	Against	Compensation	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	2.e Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	2.f Allocation of Dividends	For	For	Audit/Financials	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	2.g Ratification of Board Acts	Against	Against	Board Related	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	3. Elect Benoît Ribadeau-Dumas to the Board of Directors	Against	Against	Board Related	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	4.a Appointment of Auditor (FY2023)	For	For	Audit/Financials	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	4.b Appointment of Auditor (FY2024)	For	For	Audit/Financials	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	5. Remuneration Policy	For	For	Compensation	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	6.a Authority to Issue Shares w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	6.b Authority to Suppress Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	7. Authority to Repurchase Shares	Against	Against	Capital Management	Pilier Gouvernance
Stellantis N.V	NL00150001Q9	NL	Annual	13/04/2023	8. Cancellation of Shares	For	For	Capital Management	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	6. Ratification of Board of Directors, Former Supervisory Board and Auditors' Acts	For	For	Board Related	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	7. Authority to Set Auditor's Fees	For	For	Audit/Financials	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	8. Appointment of Auditor and Authority to Set Fees	For	For	Audit/Financials	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	9. Elect Peter Guenter to the Board of Directors	For	For	Board Related	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	10. Elect Daniel P. O'Day to the Board of Directors	For	For	Board Related	Pilier Gouvernance
Galapagos NV	BE0003818359	BE	Annual	25/04/2023	11. Elect Linda Higgins to the Board of Directors	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	2 Allocation of Profits	For	For	Audit/Financials	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	3 Ratification of Board and Management Acts	Against	Against	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	4.1 Appoint Domenico Scala as Board Chair	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	4.2 Elect Leonard Kruimer	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	4.3 Elect Martin Nicklasson	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	4.4 Elect Nicole Onetto	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	СН	Annual	26/04/2023	4.5 Elect Dr. Carole Sable	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	4.6 Elect Thomas Werner	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	5.1 Elect Martin Nicklasson as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	5.2 Elect Nicole Onetto as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	5.3 Elect Thomas Werner as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	6.1 Board Compensation	For	For	Compensation	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	6.2 Executive Compensation	For	For	Compensation	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	7.1 Amendments to Articles (Shares)	For	For	Changes to Company Statutes	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	7.2 Amendments to Articles (Hybrid Meetings)	For	For	Changes to Company Statutes	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	7.3 Amendments to Articles (Miscellaneous)	For	For	Changes to Company Statutes	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	7.4 Change of Company Headquarters	For	For	Changes to Company Statutes	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	7.5 Amendments to Articles (Company Purpose)	For	For	Changes to Company Statutes	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	8 Approval of a Capital Band	For	For	Capital Management	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	9 Appointment of Independent Proxy	For	For	Meeting Administration	Pilier Gouvernance
Basilea Pharmaceutica AG	CH0011432447	CH	Annual	26/04/2023	10 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1a. Elect Craig H. Barratt	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1b. Elect Joseph C. Beery	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1c. Elect Gary S. Guthart	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1d. Elect Amal M. Johnson	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1e. Elect Don R. Kania	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1f. Elect Amy L. Ladd	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1g. Elect Keith R. Leonard, Jr.	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	1h. Elect Alan J. Levy	For	For	Board Related	Pilier Gouvernance
Intuitive Surgical Inc		US	Annual		1i. Elect Jami Dover Nachtsheim	For	For	Board Related	Pilier Gouvernance
III UUUVE SUIRICALING	US46120E6023			27/04/2023	1i. Elect Jami Dover Nachtsneim 1i. Elect Monica P. Reed	-			
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023		For	For	Board Related	Pilier Gouvernance

		1				1_	1_	1	
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	2. Advisory Vote on Executive Compensation	For 1 Year	For For	Compensation	Pilier Gouvernance Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023		Annual	27/04/2023	3. Frequency of Advisory Vote on Executive Compensation			Compensation	
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023	4. Ratification of Auditor	For	For For	Audit/Financials	Pilier Gouvernance
Intuitive Surgical Inc	US46120E6023	US	Annual	27/04/2023 27/04/2023	5. Shareholder Proposal Regarding Median Gender and Racial Pay Equity Report	Against	-	SHP: Compensation	Pilier Gouvernance
Johnson & Johnson Johnson & Johnson	US4781601046	US	Annual Annual	27/04/2023	1a. Elect Darius Adamczyk 1b. Elect Mary C. Beckerle	For For	For For	Board Related Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046 US4781601046	US	Annual	27/04/2023	1c. Elect D. Scott Davis	For	For	Board Related	Pilier Gouvernance Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1d. Elect Jennifer A. Doudna	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1e. Elect Joaquin Duato	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1f. Elect Marillyn A. Hewson	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1g. Elect Paula A. Johnson	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1h. Elect Hubert Joly	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	11. Elect Mark B. McClellan	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1j. Elect Anne Mulcahy	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1k. Elect Mark A. Weinberger	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	1l. Elect Nadja Y. West	For	For	Board Related	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	Shareholder Proposal Regarding Adoption of Mandatory Arbitration Bylaw	Abstain	Against	SHP: Governance	Pilier Gouvernance
Johnson & Johnson	US4781601046	US	Annual	27/04/2023	7. Shareholder Proposal Prohibiting Adjustments for Legal and Compliance Costs	Abstain	Against	SHP: Compensation	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1a. Elect Ronald E. Blaylock	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1b. Elect Albert Bourla	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1c. Elect Susan Desmond-Hellmann	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1d. Elect Joseph J. Echevarria	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1e. Elect Scott Gottlieb	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1f. Elect Helen H. Hobbs	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1g. Elect Susan Hockfield	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1h. Elect Dan R. Littman	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1i. Elect Shantanu Narayen	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1j. Elect Suzanne Nora Johnson	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	1k. Elect James Quincey	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	11. Elect James C. Smith	For	For	Board Related	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	4. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	5. Shareholder Proposal Regarding Severance Approval Policy	Against	For	SHP: Compensation	Pilier Gouvernance
Pfizer Inc.	US7170811035	US	Annual	27/04/2023	6. Shareholder Proposal Regarding Independent Chair	For	Against	SHP: Governance	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	5. Remuneration Report	For	For	Compensation	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	6. Ratification of Board Acts	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	7. Ratification of Auditor's Acts	For	For	Audit/Financials	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	8.1.A Elect Jan Berger to the Board of Directors	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	8.1.B Ratification of Independence of Jan Berger	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	8.2. Elect Cyril Janssen to the Board of Directors	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	8.3.A Elect Maëlys Castella to the Board of Directors	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	8.3.B Ratification of Independence of Maëlys Castella	For	For	Board Related	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	9. Long Term Incentive Plan (Free Allocation of Shares)	For	For	Compensation	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	10.1 Change in Control Clause (EMTN Program)	For	For	Changes to Company Statutes	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	10.2 Change in Control Clause (European Investment Bank Facility Agreement)	For	For	Changes to Company Statutes	Pilier Gouvernance
UCB SA	BE0003739530	BE	Mix	27/04/2023	10.3 Change in Control Clause (Term Facility Agreement)	For	For	Changes to Company Statutes	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	2 Final Dividend	For	For	Audit/Financials	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	3 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	4 Authority to Set Auditor's Fees	For	For	Audit/Financials	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5A Elect Michel Demaré	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5B Elect Pascal Soriot	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5C Elect Aradhana Sarin	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5D Elect Philip Broadley	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5E Elect Euan Ashley	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5F Elect Deborah DiSanzo	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5G Elect Diana Layfield	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5H Elect Sherilyn S. McCoy	For	For	Board Related	Pilier Gouvernance

	1	1	1			1_	1_		1
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	51 Elect Tony MOK Shu Kam	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5J Elect Nazneen Rahman	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5K Elect Andreas Rummelt	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	5L Elect Marcus Wallenberg	For	For	Board Related	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	6 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	8 Authority to Issue Shares w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	9 Authority to Issue Shares w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	10 Authority to Issue Shares w/o Preemptive Rights (Specified Capital Investment)	For	For	Capital Management	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	11 Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	12 Authority to Set General Meeting Notice Period at 14 Days	For	For	Changes to Company Statutes	Pilier Gouvernance
Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	13 Adoption of New Articles	For	For	Changes to Company Statutes	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1a. Elect Robert J. Alpern	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1b. Elect Claire Babineaux-Fontenot	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1c. Elect Sally E. Blount	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1d. Elect Robert B. Ford	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1e. Elect Paola Gonzalez	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1f. Elect Michelle A. Kumbier	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1g. Elect Darren W. McDew	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1h. Elect Nancy McKinstry	Against	Against	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1i. Elect Michael G. O'Grady	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1j. Elect Michael F. Roman	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1k. Elect Daniel J. Starks	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	1l. Elect John G. Stratton	For	For	Board Related	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	4. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	5. Shareholder Proposal Regarding Right to Call Special Meetings	Against	For	SHP: Governance	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	6. Shareholder Proposal Regarding Independent Chair	For	Against	SHP: Governance	Pilier Gouvernance
Abbott Laboratories	US0028241000	US	Annual	28/04/2023	8. Shareholder Proposal Prohibiting Adjustments for Legal and Compliance Costs	For	Against	SHP: Compensation	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1a. Elect José E. Almeida	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1b. Elect Michael F. Mahoney	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1c. Elect Patricia Morrison	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1d. Elect Stephen N. Oesterle	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1e. Elect Nancy M. Schlichting	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1f. Elect Brent Shafer	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1g. Elect Catherine R. Smith	Against	Against	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1h. Elect Amy M. Wendell	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1i. Elect David S. Wilkes	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	1j. Elect Peter M. Wilver	For	For	Board Related	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	2. Advisory Vote on Executive Compensation	Against	Against	Compensation	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	5. Shareholder Proposal Regarding Severance Approval Policy	Against	For	SHP: Compensation	Pilier Gouvernance
Baxter International Inc.	US0718131099	US	Annual	02/05/2023	6. Shareholder Proposal Regarding Retention of Shares Until Normal Retirement Age	Against	For	SHP: Compensation	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1A. Elect Peter J. Arduini	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1B. Elect Deepak L. Bhatt	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1C. Elect Giovanni Caforio	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1D. Elect Julia A. Haller	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1E. Elect Manuel Hidalgo Medina	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1F. Elect Paula A. Price	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1G. Elect Derica W. Rice	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1H. Elect Theodore R. Samuels, II	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	11. Elect Gerald Storch	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1). Elect Karen H. Vousden	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	1K. Elect Phyllis R. Yale	For	For	Board Related	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	5. Shareholder Proposal Regarding Independent Chair	For	Against	SHP: Governance	Pilier Gouvernance
Bristol-Myers Squibb Co.	US1101221083	US	Annual	02/05/2023	7. Shareholder Proposal Regarding Allowing Beneficial Owners to Call Special Meetings	Against	For	SHP: Governance	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	3. Remuneration Report	Against	Against	Compensation	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	4.b. Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance

	1	1	- I.		and the second s	1_	1_		I
Argenx SE	NL0010832176	BE	Annual	02/05/2023	4.d. Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	4.e. Ratification of Board Acts	For	For	Board Related	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	5. Elect Joseph Donald deBethizy to the Board of Directors	For	For	Board Related	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	6. Authority to Issue Shares w/ or w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Argenx SE	NL0010832176	BE	Annual	02/05/2023	7. Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1a. Elect Jacqueline K. Barton	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1b. Elect Jeffrey A. Bluestone	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1c. Elect Sandra J. Horning	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1d. Elect Kelly A. Kramer	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1e. Elect Kevin E. Lofton	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1f. Elect Harish Manwani	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1g. Elect Daniel P. O'Day	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1h. Elect Javier J. Rodriguez	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	1i. Elect Anthony Welters	For	For	Board Related	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	4. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	5. Amendment to the Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	6. Shareholder Proposal Regarding Multiple Board Nominees	Against	For	SHP: Governance	Pilier Gouvernance
Gilead Sciences, Inc.	US3755581036	US	Annual	03/05/2023	7. Shareholder Proposal Regarding Allowing Beneficial Owners to Call Special Meetings	Against	For	SHP: Governance	Pilier Gouvernance
Moderna Inc	US60770K1079	US	Annual	03/05/2023	1.01 Elect Stephen Berenson	For	For	Board Related	Pilier Gouvernance
Moderna Inc	US60770K1079	US	Annual	03/05/2023	1.02 Elect Sandra J. Horning	For	For	Board Related	Pilier Gouvernance
Moderna Inc	US60770K1079	US	Annual	03/05/2023	1.03 Elect Paul Sagan	For	For	Board Related	Pilier Gouvernance
Moderna Inc	US60770K1079	US	Annual	03/05/2023	2. Advisory Vote on Executive Compensation	Against	Against	Compensation	Pilier Gouvernance
Moderna Inc	US60770K1079	US	Annual	03/05/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	2 Remuneration Report	For	For	Compensation	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	3 Elect Julie Brown	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	4 Elect Vishal Sikka	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	5 Elect Elizabeth McKee Anderson	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	6 Elect Sir Jonathan R. Symonds	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	7 Elect Emma N. Walmsley	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	8 Elect Charles A. Bancroft	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	9 Elect Hal V. Barron	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	10 Elect Anne Beal	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	11 Elect Harry Dietz	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	12 Elect Jesse Goodman	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	13 Elect Urs Rohner	For	For	Board Related	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	14 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	15 Authority to Set Auditor's Fees	For	For	Audit/Financials	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	16 Amendment to Remuneration Policy	For	For	Compensation	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	18 Authority to Issue Shares w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	19 Authority to Issue Shares w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
GSK Plc	GB00BN7SWP63		Annual	03/05/2023	20 Authority to Issue Shares w/o Preemptive Rights (Specified Capital Investment)	For	For	Capital Management	Pilier Gouvernance
GSK Plc	GB00BN7SWP63		Annual	03/05/2023	21 Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
GSK Plc	GB00BN7SWP63		Annual	03/05/2023	23 Authority to Set General Meeting Notice Period at 14 Days	For	For	Changes to Company Statutes	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1a. Elect Nelda J. Connors	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1b. Elect Charles J. Dockendorff	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1c. Elect Yoshiaki Fujimori	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1d. Elect Edward J. Ludwig	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1e. Elect Michael F. Mahoney	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1f. Elect David J. Roux	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1g. Elect John E. Sununu	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1h. Elect David S. Wichmann	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	1i. Elect Ellen M. Zane	For	For	Board Related	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Boston Scientific Corp.	US1011371077	US	Annual	04/05/2023	Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	1.1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	2 Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	3 Ratification of Board and Management Acts	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438		Annual	04/05/2023	4.1.1 Elect Mathieu Simon	For	For	Board Related	Pilier Gouvernance
100.50 200	C5505405456	1011	Zimadi	0-7,03,2023	1212 Elect interior sinor	1. 51		Dodia nelucu	ci Gouvernance

Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.2 Elect Joern Aldag	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.3 Elect Jean-Paul Clozel	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.4 Elect Felix R. Ehrat	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.5 Elect Srishti Gupta	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.6 Elect Peter N. Kellogg	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.7 Elect Sandy Mahatme	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.1.8 Elect Sophie Kornowski	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.2 Appoint Mathieu Simon as Board Chair	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.3.1 Elect Felix R. Ehrat	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.3.2 Elect Srishti Gupta	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.3.3 Elect Mathieu Simon	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	4.3.4 Elect Sophie Kornowski-Bonnet	For	For	Board Related	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	5.1 Board Compensation	For	For	Compensation	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	5.2 Executive Compensation	For	For	Compensation	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	6 Appointment of Independent Proxy	For	For	Meeting Administration	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	7 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	8.1 Amendments to Articles	For	For	Changes to Company Statutes	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	8.3 Capital Band	Against	Against	Capital Management	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	8.4 Amendments to Articles (Cap on Dilutive Issuances)	For	For	Changes to Company Statutes	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	8.5 Amendments to Articles (Miscellaneous)	For	For	Changes to Company Statutes	Pilier Gouvernance
Idorsia Ltd	CH0363463438	CH	Annual	04/05/2023	8.6 Amendments to Articles (Various)	For	For	Changes to Company Statutes	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	1a. Elect Robert J. Alpern	For	For	Board Related	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	1b. Elect Melody B. Meyer	For	For	Board Related	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	1c. Elect Frederick H. Waddell	For	For	Board Related	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	4. Elimination of Supermajority Requirement	For	For	Changes to Company Statutes	Pilier Gouvernance
Abbvie Inc	US00287Y1091	US	Annual	05/05/2023	5. Shareholder Proposal Regarding Simple Majority Vote	Against	For	SHP: Governance	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	1A. Elect Bernadette Connaughton	For	For	Board Related	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	1B. Elect Moni Miyashita	For	For	Board Related	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	1C. Elect Matthew L. Posard	For	For	Board Related	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Halozyme Therapeutics Inc.	US40637H1095	US	Annual	05/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	2 Ratification of Board and Management Acts	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	3 Allocation of Dividends	For	For	Audit/Financials	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	4.1 Compensation Report	For	For	Compensation	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	4.2 Board Compensation	For	For	Compensation	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	4.3 Executive Compensation	For	For	Compensation	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	5.1 Elect F. Michael Ball as Chair	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	5.2 Elect Lynn Dorsey Bleil	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	5.3 Elect Raquel C. Bono	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.4 Elect Arthur Cummings	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.5 Elect David J. Endicott	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.6 Elect Thomas Glanzmann	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.7 Elect D. Keith Grossman	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.8 Elect Scott H. Maw	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.9 Elect Karen J. May	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.10 Elect Ines Pöschel	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	5.11 Elect Dieter Spälti	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	6.1 Elect Thomas Glanzmann as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	6.2 Elect Scott H. Maw as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	6.3 Elect Karen J. May as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	6.4 Elect Ines Pöschel as Compensation Committee Member	For	For	Board Related	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	7 Appointment of Independent Proxy	For	For	Meeting Administration	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	8 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	9.1 Introduction of a Capital Band	For	For	Capital Management	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	9.2 Increase in Conditional Capital	For	For	Capital Management	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	9.3 Amendments to Articles (Share Capital)	For	For	Changes to Company Statutes	Pilier Gouvernance
Alcon Inc.	CH0432492467	CH	Annual	05/05/2023	9.4 Amendments to Articles (Shareholder Meetings)	For	For	Changes to Company Statutes	Pilier Gouvernance
Alcon Inc.	CH0432492467	СН	Annual	05/05/2023	9.5 Amendments to Articles (Board of Directors)	For	For	Changes to Company Statutes	Pilier Gouvernance
1	1	-	_		· · · · · · · · · · · · · · · · · · ·	-	-		

Alexa Inc	CU04224024C7	CII	Americal	05 (05 (2022	0.C. Americka and Anticles (Community)	F	F	Character Comment State Acc	Dilian Camanana
Alcon Inc. Mirati Therapeutics Inc	CH0432492467 US60468T1051	CH US	Annual Annual	05/05/2023 11/05/2023	9.6 Amendments to Articles (Compensation) 1.01 Elect Charles M. Baum	For	For For	Changes to Company Statutes Board Related	Pilier Gouvernance
·						For	For		Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.02 Elect Bruce L.A. Carter			Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.03 Elect Julie Cherrington	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.04 Elect Aaron Davis	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.05 Elect Faheem Hasnain	Withhold	Against	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.06 Elect Craig A. Johnson	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.07 Elect Maya Martinez-Davis	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.08 Elect David Meek	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	1.09 Elect Shalini Sharp	For	For	Board Related	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Annual	11/05/2023	4. Amendment to the 2013 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	1. Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2A. Elect Simon TO Chi Keung	Against	Against	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2B. Elect Weiguo SU	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2C. Elect Johnny CHENG Chig Fung	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2D. Elect Dan Eldar	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2E. Elect Edith SHIH	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2F. Elect Lefei SUN	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2G. Elect Paul R. Carter	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	2H. Elect Graeme A. Jack	Against	Against	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	21. Elect Tony MOK Shu Kam	For	For	Board Related	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	Appointment of Auditor and Authority to Set Fees	For	For	Audit/Financials	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	Appointment of Addition and Additionally to Services Authority to Issue Shares w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
HUTCHMED (China) Limited	KYG4672N1198	KY	Annual	12/05/2023	5. Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
		FR	Mix		2 Consolidated Accounts and Reports	For	For		Pilier Gouvernance
Innate Pharma Innate Pharma	FR0010331421	FR	Mix	12/05/2023	3 Allocation of Losses	For		Audit/Financials Audit/Financials	
	FR0010331421	FR		12/05/2023		For	For For		Pilier Gouvernance
Innate Pharma	FR0010331421		Mix	12/05/2023	4 Special Auditors Report On Regulated Agreements			Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	5 Elect Irina Staatz-Granzer	Against	Against	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	6 Elect Véronique Chabernaud	Against	Against	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	7 Elect Olivier Martinez	For	For	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	8 Elect Jean-Yves Blay	Against	Against	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	9 Elect Gilles Brisson	Against	Against	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	10 Elect Hervé Brailly	For	For	Board Related	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	11 2023 Supervisory Board Members' Fees	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	12 2023 Remuneration Policy (Executives)	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	13 2023 Remuneration Policy (Management Board Chair)	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	14 2023 Remuneration Policy (Management Board Members)	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	15 2023 Remuneration Policy (Supervisory Board Chair)	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	16 2023 Remuneration Policy (Supervisory Board Members)	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	18 2022 Remuneration of Mondher Majoubi, Management Board Chair	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	19 2022 Remuneration of Yannis Morel, Management Board Member	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	20 2022 Remuneration of Hervé Brailly, Supervisory Board Chair	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	21 Authority to Repurchase and Reissue Shares	For	For	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	22 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	23 Authority to Issue Shares w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	24 Authority to Issue Shares Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	25 Authority to Set Offering Price of Shares	Against	Against	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	26 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Qualified Investors)	Against	Against	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	27 Authority to Issue Shares In the Form of ADS w/o Preemptive Rights (ATM Program)	Against	Against	Capital Management	Pilier Gouvernance
	FR0010331421 FR0010331421	FR	Mix		28 Greenshoe		_		Pilier Gouvernance
Innate Pharma		FR	Mix	12/05/2023		Against	Against	Capital Management	
Innate Pharma	FR0010331421			12/05/2023	29 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	30 Authority to Increase Capital in Case of Exchange Offers	For	For	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	31 Global Ceiling on Capital Increases	For	For	Capital Management	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	32 Authority to Issue Performance Shares to (Executives)	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	33 Authority to Issue Performance Shares to (Employees)	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	34 Authority to Issue Restricted Shares	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	35 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	36 Authority to Grant Warrants (Supervisory Board Members)	Against	Against	Compensation	Pilier Gouvernance
Innate Pharma	FR0010331421	FR	Mix	12/05/2023	37 Authority to Cancel Shares and Reduce Capital	Against	Against	Capital Management	Pilier Gouvernance
Innete Disease	FR0010331421	FR	Mix	12/05/2023	38 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Innate Pharma	110010331421	111	IVIIA	12/03/2023	So Mathonisation of Eegan of Mathoes	1 01	1 01	Wiccing Administration	Tiller douvernance

Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	1.02 Elect Gary Lyons	For	For	Board Related	Pilier Gouvernance
Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	1.03 Elect Johanna Mercier	For	For	Board Related	Pilier Gouvernance
Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	4. Amendment to the 2020 Equity Incentive Plan	For	For	Compensation	Pilier Gouvernance
Neurocrine Biosciences, Inc.	US64125C1099	US	Annual	17/05/2023	5. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.1 Elect Sangeeta N. Bhatia	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.2 Elect Lloyd A. Carney	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.3 Elect Alan M. Garber	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.4 Elect Terrence C. Kearney	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.5 Elect Reshma Kewalramani	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.6 Elect Jeffrey M. Leiden	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.7 Elect Diana L. McKenzie	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.8 Elect Bruce I. Sachs	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	1.9 Elect Suketu Upadhyay	For	For	Board Related	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Vertex Pharmaceuticals, Inc.	US92532F1003	US	Annual	17/05/2023	4. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	2 Ratification of Management Board Acts	For	For	Board Related	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	3 Ratification of Supervisory Board Acts	For	For	Board Related	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	4 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	5.1 Elect Michael L. Brosnan	For	For	Board Related	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	5.2 Elect George Golumbeski	For	For	Board Related	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	6 Increase in Authorised Capital I	For	For	Capital Management	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	7 Increase in Authorised Capital II	For	For	Capital Management	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	8 Cancellation of Authorised Capital	For	For	Capital Management	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	9 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	10.1 Amendments to Articles (Virtual Meetings)	For	For	Changes to Company Statutes	Pilier Gouvernance
Morphosys AG	DE0006632003	DE	Annual	17/05/2023	10.2 Amendments to Articles (Virtual AGM Participation of Supervisory Board Members)	Against	Against	Changes to Company Statutes	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	1a. Elect Michael W. Bonney	For	For	Board Related	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	1b. Elect Yvonne Greenstreet	For	For	Board Related	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	1c. Elect Phillip A. Sharp	For	For	Board Related	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	1d. Elect Elliott Sigal	For	For	Board Related	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Alnylam Pharmaceuticals Inc	US02043Q1076	US	Annual	18/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1a. Elect Wanda M. Austin	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1b. Elect Robert A. Bradway	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1c. Elect Michael V. Drake	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1d. Elect Brian J. Druker	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1e. Elect Robert A. Eckert	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1f. Elect Greg C. Garland	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1g. Elect Charles M. Holley, Jr.	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1h. Elect S. Omar Ishrak	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1i. Elect Tyler Jacks	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1j. Elect Ellen J. Kullman	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1k. Elect Amy E. Miles	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1l. Elect Ronald D. Sugar	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	1m. Elect R. Sanders Williams	For	For	Board Related	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
AMGEN Inc.	US0311622098	US	Annual	19/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1a. Elect Douglas M. Baker, Jr.	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1b. Elect Mary Ellen Coe	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1c. Elect Pamela J. Craig	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1d. Elect Robert M. Davis	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1e. Elect Thomas H. Glocer	For	For	Board Related	Pilier Gouvernance
		US							
Merck & Co Inc Merck & Co Inc	US58933Y1055 US58933Y1055	US	Annual Annual	23/05/2023 23/05/2023	1f. Elect Risa Lavizzo-Mourey	For For	For For	Board Related Board Related	Pilier Gouvernance Pilier Gouvernance
			Annual		1g. Elect Stephen L. Mayo 1h. Elect Paul B. Rothman	For			
Merck & Co Inc	US58933Y1055	US		23/05/2023			For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055 US58933Y1055	US	Annual	23/05/2023	1i. Elect Patricia F. Russo	For For	For For	Board Related Board Related	Pilier Gouvernance Pilier Gouvernance
Merck & Co Inc			Annual	23/05/2023	1j. Elect Christine E. Seidman				

	1			/ /	and the contract of the contra	_	1_	I	I
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1k. Elect Inge G. Thulin	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	11. Elect Kathy J. Warden	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	1m. Elect Peter C. Wendell	For	For	Board Related	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Merck & Co Inc	US58933Y1055	US	Annual	23/05/2023	10. Shareholder Proposal Regarding Independent Chair	For	Against	SHP: Governance	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	2 Consolidated Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	3 Ratification of Board Acts	Against	Against	Board Related	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	4 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	5 Related Party Transactions (Fondation Christophe and Rodolphe Merieux)	For	For	Board Related	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	6 Related Party Transactions (Specific Diagnostics)	For	For	Board Related	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	7 Elect Philippe Archinard	Against	Against	Board Related	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	8 Appointment of Auditor (Grant Thornton)	For	For	Audit/Financials	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	9 2023 Remuneration Policy (Corporate Officers)	Against	Against	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	10 2023 Remuneration Policy (Chair and CEO)	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	11 2023 Remuneration Policy (Deputy CEO)	Against	Against	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	12 2023 Remuneration Policy (Board of Directors)	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	13 2022 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	14 2022 Remuneration of Alexandre Merieux, Chair and CEO	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	15 2022 Remuneration of Pierre Boulud, Deputy CEO	Against	Against	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	16 Authority to Repurchase and Reissue Shares	For	For	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	17 Authority to Cancel Shares and Reduce Capital	For	For	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	18 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	19 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	20 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights in Case of Exchange Offer	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	21 Authority to Set Offering Price of Shares	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	22 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	23 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	24 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	25 Authority to Issue Shares w/o Preemptive Rights in Consideration for Securities Issued by Subsidiaries	Against	Against	Capital Management	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	26 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	27 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	28 Removal of Preemptive Rights Rights in Favour of Beneficiaries of Employee Stock Purchase Plans	For	For	Compensation	Pilier Gouvernance
Biomerieux	FR0013280286	FR	Mix	23/05/2023	29 Global Ceiling on Capital Increases and Debt Issuances	For	For	Capital Management	Pilier Gouvernance
Biomerieux Biomerieux	FR0013280286 FR0013280286	FR FR	Mix Mix	23/05/2023 23/05/2023	29 Global Ceiling on Capital Increases and Debt Issuances 30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"")	For For	For For	Capital Management Audit/Financials	Pilier Gouvernance Pilier Gouvernance
						For For			
Biomerieux	FR0013280286	FR	Mix	23/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"")	For	For	Audit/Financials	Pilier Gouvernance
Biomerieux Biomerieux	FR0013280286 FR0013280286	FR FR	Mix Mix	23/05/2023 23/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities	For For	For For	Audit/Financials Meeting Administration	Pilier Gouvernance Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper	For For	For For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023	FR FR US US	Mix Mix Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai	For For For	For For For	Audit/Financials Meeting Administration Board Related Board Related	Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023	FR FR US US US	Mix Mix Annual Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Melson J. Chai 1c. Elect Ruby R. Chandy	For For For For	For For For For	Audit/Financials Meeting Administration Board Related Board Related Board Related	Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US US US US	Mix Mix Annual Annual Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris	For For For For For	For For For For For	Audit/Financials Meeting Administration Board Related Board Related Board Related Board Related	Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US US US US US US	Mix Mix Annual Annual Annual Annual Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks	For For For For For For For	For For For For For For For	Audit/Financials Meeting Administration Board Related Board Related Board Related Board Related Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US US US US US US US	Mix Mix Annual Annual Annual Annual Annual Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith	For For For For For For For For For	For For For For For For For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual Annual Annual Annual Annual Annual Annual Annual Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen	For	For For For For For For For For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect Tyler Jacks 1f. Elect James C. Mullen 1h. Elect Lars R. Sørensen	For	For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Ruby R. Chandy 1d. Elect Ruby R. Chandy 1d. Elect Tyler Jacks 1f. Elect Tyler Jacks 1f. Elect A. Alexandra Keith 1g. Elect Lars R. Sørensen 1h. Elect Lars R. Sørensen 1i. Elect Debora L. Spar	For	For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Ruby R. Chandy 1d. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect Lars R. Sørensen 1i. Elect Lars R. Sørensen 1j. Elect Scott M. Sperling	For	For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Door L. Spar 1j. Elect Scott M. Sperling 1k. Elect Soot M. Sperling 1k. Elect Dion J. Weisler	For	For	Audit/Financials Meeting Administration Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Debora L. Spar 1j. Elect Cott M. Sperling 1k. Elect Dion J. Weisler 2. Advisory Vote on Executive Compensation	For	For	Audit/Financials Meeting Administration Board Related Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Ruby R. Chandy 1d. Elect Ruby R. Chandy 1d. Elect Tyler Jacks 1f. Elect Tyler Jacks 1f. Elect James C. Mullen 1h. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Scott M. Sperling 1k. Elect Scott M. Sperling 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation	For	For	Audit/Financials Meeting Administration Board Related Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") Authorisation of Legal Formalities Elect Marc N. Casper Elect Nelson J. Chai Elect Ruby R. Chandy d. Elect C. Martin Harris Elect Tyler Jacks Elect R. Alexandra Keith Elect Lars R. Sørensen i. Elect Lars R. Sørensen ii. Elect Lars N. Sperling Elect Debora L. Spar j. Elect Dion J. Weisler Advisory Vote on Executive Compensation Frequency of Advisory Vote on Executive Compensation A. Ratification of Auditor	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Audit/Financials	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Dobora L. Spar 1j. Elect Scott M. Sperling 1k. Elect Dion J. Weisler 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation 4. Ratification of Auditor 5. Amendment to the 2013 Stock Incentive Plan	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Audit/Financials Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyle Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Debora L. Spar 1j. Elect Debora L. Spar 1j. Elect Door J. Weisler 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation 4. Ratification of Auditor 5. Amendment to the 2013 Stock Incentive Plan 6. Approval of the 2023 Employee Stock Purchase Plan	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Compensation Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc.	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 12. Elect Nelson J. Chai 13. Elect Nelson J. Chai 14. Elect Ruby R. Chandy 15. Elect T. Martin Harris 16. Elect T. Martin Harris 17. Elect S. Martin Harris 18. Elect James C. Mullen 19. Elect Lars R. Sørensen 19. Elect Lars R. Sørensen 19. Elect Debora L. Spar 19. Elect Doin J. Weisler 20. Advisory Vote on Executive Compensation 30. Frequency of Advisory Vote on Executive Compensation 41. Ratification of Auditor 42. Amendment to the 2013 Stock Incentive Plan 43. Approval of the 2023 Employee Stock Purchase Plan 44. Consolidated Accounts and Reports	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Compensation Compensation Audit/Financials Compensation Audit/Financials	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 FR000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 12 Elect Marc N. Casper 13 Elect Ruby R. Chandy 14 Elect C. Martin Harris 15 Elect Tyler Jacks 16 Elect James C. Mullen 17 Elect James C. Mullen 18 Elect James C. Mullen 19 Elect Lars R. Sørensen 10 Elect Lobora L. Spar 10 Elect Scott M. Sperling 11 Elect Scott M. Sperling 12 Advisory Vote on Executive Compensation 13 Frequency of Advisory Vote on Executive Compensation 14 Ratification of Auditor 15 Amendment to the 2013 Stock Incentive Plan 16 Approval of the 2023 Employee Stock Purchase Plan 2 Consolidated Accounts and Reports 3 Allocation of Profits/Dividends	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Audit/Financials Compensation Audit/Financials Audit/Financials	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi Sanofi	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US883561023 US8835561023 US8835561023 US8835561023 US8835561023 FR000120578 FR0000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023 25/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Dobora L. Spar 1j. Elect Scott M. Sperling 1k. Elect Dion J. Weisler 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation 4. Ratification of Auditor 5. Amendment to the 2013 Stock Incentive Plan 6. Approval of the 2023 Employee Stock Purchase Plan Consolidated Accounts and Reports 3 Allocation of Profits/ Dividends 4 Elect Frédéric Oudéa	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Compensation Audit/Financials Compensation Audit/Financials Board Related Board Related Board Related	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi Sanofi Sanofi	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 FR000120578 FR0000120578 FR0000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect T. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1l. Elect Debora L. Spar 1j. Elect Debora L. Spar 1j. Elect Dion J. Weisler 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation 4. Ratification of Auditor 5. Amendment to the 2013 Stock Incentive Plan 6. Approval of the 2023 Employee Stock Purchase Plan 2. Consolidated Accounts and Reports 3. Allocation of Profits/Dividends 4. Elect Frédéric Oudéa 5. 2022 Remuneration Report	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Audit/Financials Audit/Financials Audit/Financials Board Related Compensation Audit/Financials Board Related Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi Sanofi Sanofi Sanofi	FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 FR000120578 FR0000120578 FR0000120578 FR0000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 12. Elect Merc N. Casper 13. Elect Ruby R. Chandy 14. Elect Ruby R. Chandy 15. Elect T. Martin Harris 16. Elect T. Martin Harris 17. Elect R. Alexandra Keith 18. Elect James C. Mullen 19. Elect Lars R. Sørensen 19. Elect Lars R. Sørensen 19. Elect Debora L. Spar 19. Elect Debora L. Spar 19. Elect Dion J. Weisler 20. Advisory Vote on Executive Compensation 31. Frequency of Advisory Vote on Executive Compensation 42. Ratification of Auditor 43. Amendment to the 2013 Stock Incentive Plan 44. Approval of the 2023 Employee Stock Purchase Plan 45. Allocation of Profits/Dividends 46. Elect Frédéric Oudéa 47. Elect Frédéric Oudéa 48. Elect Frédéric Oudéa 49. Allocation of Profits/Dividends 40. Elect Frédéric Oudéa 49. Allocation of Profits/Dividends 40. Elect Frédéric Oudéa 40. Elect Frédéric Oudéa 40. Elect Frédéric Oudéa 40. Elect Frédéric Oudéa 41. Elect Frédéric Oudéa 42. Elect Frédéric Oudéa 43. Allocation of Profits/Dividends 44. Elect Frédéric Oudéa 45. 2022 Remuneration Report	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Audit/Financials Compensation Audit/Financials Audit/Financials Audit/Financials Audit/Financials Compensation Compensation Compensation Compensation Compensation Audit/Financials Audit/Financials Compensation Compensation Compensation Compensation Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi Sanofi Sanofi Sanofi Sanofi	FR0013280286 FR0013280286 FR0013280286 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 US8835561023 FR000120578 FR000120578 FR0000120578 FR0000120578 FR0000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 12. Elect Melson J. Chai 32. Elect Nelson J. Chai 33. Elect Ruby R. Chandy 34. Elect C. Martin Harris 35. Elect Tyler Jacks 46. Elect Tyler Jacks 47. Elect James C. Mullen 48. Elect James C. Mullen 49. Elect Lars R. Sørensen 49. Elect Lars R. Sørensen 49. Elect Scott M. Sperling 49. Elect Scott M. Sperling 40. Elect Scott M. Sperling 40. Advisory Vote on Executive Compensation 40. Ratification of Auditor 41. Amendment to the 2013 Stock Incentive Plan 42. Consolidated Accounts and Reports 43. Allocation of Profits/Dividends 44. Elect Frédéric Oudéa 45. 2022 Remuneration of Serge Weinberg, Chair 46. 2022 Remuneration of Serge Weinberg, Chair 47. 2022 Remuneration of Paul Hudson, CEO	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Audit/Financials Compensation Audit/Financials Audit/Financials Board Related Compensation	Pilier Gouvernance
Biomerieux Biomerieux Thermo Fisher Scientific Inc. Sanofi Sanofi Sanofi Sanofi Sanofi	FR0013280286 FR0013280286 US8835561023 FR000120578 FR0000120578 FR0000120578 FR0000120578 FR0000120578 FR0000120578 FR0000120578 FR0000120578	FR FR US	Mix Mix Annual	23/05/2023 23/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 24/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023 25/05/2023	30 Acknowledgement of the Non-Conversion to a Corporate Form Societas Europaea (""SE"") 31 Authorisation of Legal Formalities 1a. Elect Marc N. Casper 1b. Elect Nelson J. Chai 1c. Elect Ruby R. Chandy 1d. Elect C. Martin Harris 1e. Elect Tyler Jacks 1f. Elect R. Alexandra Keith 1g. Elect James C. Mullen 1h. Elect Lars R. Sørensen 1i. Elect Scott M. Sperling 1k. Elect Dion J. Weisler 2. Advisory Vote on Executive Compensation 3. Frequency of Advisory Vote on Executive Compensation 4. Ratification of Auditor 5. Amendment to the 2013 Stock Incentive Plan 6. Approval of the 2023 Employee Stock Purchase Plan 2. Consolidated Accounts and Reports 3. Allocation of Profits/ Dividends 4. Elect Frédéric Oudéa 5. 2022 Remuneration Report 6. 2022 Remuneration of Paul Hudson, CEO 8. 2023 Directors' Fees	For	For	Audit/Financials Meeting Administration Board Related Compensation Compensation Compensation Audit/Financials Compensation Audit/Financials Board Related Compensation	Pilier Gouvernance

Sanofi	FR0000120578	FR	Mix	25/05/2023	11 2023 Remuneration Policy (CEO)	For	For	Compensation	Pilier Gouvernance
Sanofi		FR	Mix	25/05/2023	12 Appointment of Auditor (PwC)	Against	Against	Audit/Financials	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	13 Relocation of Corporate Headquarters	For	For	Changes to Company Statutes	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	14 Authority to Repurchase and Reissue Shares	For	For	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	15 Authority to Cancel Shares and Reduce Capital	For	For	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	16 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	17 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	18 Authority to Issue Shares and/or Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	19 Authority to Issue Debt Instruments	For	For	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	20 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	21 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	22 Authority to Increase Capital in Consideration to Contributions in Kind	For	For	Capital Management	Pilier Gouvernance
Sanofi		FR	Mix	25/05/2023	23 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Sanofi	FR0000120578	FR	Mix	25/05/2023	24 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Relay Therapeutics Inc	US75943R1023	US	Annual	31/05/2023	1.1 Elect Douglas S. Ingram	For	For	Board Related	Pilier Gouvernance
Relay Therapeutics Inc	US75943R1023	US	Annual	31/05/2023	1.2 Elect Sekar Kathiresan	For	For	Board Related	Pilier Gouvernance
Relay Therapeutics Inc		US	Annual	31/05/2023	1.3 Elect Jami Rubin	For	For	Board Related	Pilier Gouvernance
Relay Therapeutics Inc	US75943R1023 US75943R1023	US	Annual	31/05/2023	2. Advisory Vote on Executive Compensation	Against	Against	Compensation	Pilier Gouvernance
		US	Annual		3. Ratification of Auditor	For	_	Audit/Financials	Pilier Gouvernance
Relay Therapeutics Inc	US75943R1023			31/05/2023			For	· '	
Ipsen	FR0010259150	FR FR	Mix	31/05/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Ipsen			Mix	31/05/2023	2 Consolidated Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
lpsen .	FR0010259150	FR	Mix	31/05/2023	3 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
lpsen .	FR0010259150	FR	Mix	31/05/2023	4 Special Auditors Report on Regulated Agreements	For	For	Board Related	Pilier Gouvernance
Ipsen		FR	Mix	31/05/2023	5 Appointment of Auditor (KPMG)	Against	Against	Audit/Financials	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	6 Elect Marc de Garidel	Against	Against	Board Related	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	7 Elect Henri Beaufour	Against	Against	Board Related	Pilier Gouvernance
lpsen .		FR	Mix	31/05/2023	8 Elect Michèle Ollier	Against	Against	Board Related	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	9 2023 Remuneration Policy (Board of Directors)	For	For	Compensation	Pilier Gouvernance
lpsen	FR0010259150	FR	Mix	31/05/2023	10 2023 Remuneration Policy (Chair)	For	For	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	11 2023 Remuneration Policy (CEO and Other Executives)	For	For	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	12 2022 Remuneration Report	Against	Against	Compensation	Pilier Gouvernance
Ipsen		FR	Mix	31/05/2023	13 2022 Remuneration of Marc de Garidel, Chair	Against	Against	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	14 2022 Remuneration of David Loew, CEO	For	For	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	15 Authority to Repurchase and Reissue Shares	For	For	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	16 Authority to Cancel Shares and Reduce Capital	For	For	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	17 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	18 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Ipsen		FR	Mix	31/05/2023	19 Authority to Increase Capital in Case of Exchange Offers	Against	Against	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	20 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	21 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	22 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	23 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	24 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	25 Amendments to Articles Regarding Chair Age Limits	For	For	Changes to Company Statutes	Pilier Gouvernance
Ipsen	FR0010259150	FR	Mix	31/05/2023	26 Amendments to Articles Regarding Board Meetings' Minutes	For	For	Changes to Company Statutes	Pilier Gouvernance
Ipsen		FR	Mix	31/05/2023	27 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Editas Medicine Inc	US28106W1036	US	Annual	01/06/2023	1.01 Elect Bernadette Connaughton	For	For	Board Related	Pilier Gouvernance
Editas Medicine Inc	US28106W1036	US	Annual	01/06/2023	1.02 Elect Elliott Levy	For	For	Board Related	Pilier Gouvernance
Editas Medicine Inc		US	Annual	01/06/2023	1.03 Elect Akshay K. Vaishnaw	Withhold	Against	Board Related	Pilier Gouvernance
Editas Medicine Inc		US	Annual	01/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Editas Medicine Inc	US28106W1036	US	Annual	01/06/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	1.01 Elect Spencer R. Berthelsen	For	For	Board Related	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	1.02 Elect Joan E. Herman	For	For	Board Related	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	1.03 Elect B. Lynne Parshall	For	For	Board Related	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	1.04 Elect Joseph H. Wender	Withhold	Against	Board Related	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	4. Amendment to the 2011 Equity Incentive Plan	For	For	Compensation	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	5. Amendment to the 2002 Non-Employee Directors' Stock Option Plan	For	For	Compensation	Pilier Gouvernance
Ionis Pharmaceuticals Inc	US4622221004	US	Annual	01/06/2023	6. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.1 Elect Courtney Beers	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.2 Elect Robert F. Carey	For	For	Board Related	Pilier Gouvernance

Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.3 Elect Kenneth J. Hillan	Against	Against	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.4 Elect Margaret A. Horn	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.5 Elect Alexander D. Macrae	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.6 Elect John H. Markels	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.7 Elect James R. Meyers	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.8 Elect H. Stewart Parker	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	1.9 Elect Karen L. Smith	For	For	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	4. Amendment to the 2018 Equity Incentive Plan	For	For	Compensation	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	Increase in Authorized Common Stock	For	For	Capital Management	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	6. Amendment to Articles to Reflect New Delaware Law Provisions Regarding Officer Exculpation	Against	Against	Board Related	Pilier Gouvernance
Sangamo Therapeutics Inc	US8006771062	US	Annual	01/06/2023	7. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	2 Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	3 Special Auditors Report on Regulated Agreements	For	For	Board Related	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	4 Ratification of Co-option of Marc de Garidel	For	For	Board Related	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	5 2022 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	6 2022 Remuneration of Philippe Pouletty, Former Chair	For	For	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	7 2022 Remuneration of Corinna zur Bonsen-Thomas, Chair	For	For	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	8 2022 Remuneration of Hartmut Ehrlich, CEO	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	9 2023 Remuneration Policy (Chair)	For	For	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	10 2023 Remuneration Policy (CEO)	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	11 2023 Remuneration Policy (Board of Directors)	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	12 Authority to Repurchase and Reissue Shares	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	13 Authority to Cancel Shares and Reduce Capital	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	14 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	15 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	16 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Qualified Investors)	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	17 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	18 Authority to Set Offering Price of Shares	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	19 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	20 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	21 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	22 Authority to Increase Capital in Case of Exchange Offers	Against	Against	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	23 Global Ceiling on Capital Increases and Debt Issuances	For	For	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	24 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	25 Authority to Grant Warrants	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	26 Authority to Issue Restricted Shares	Against	Against	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	27 Global Ceiling on Capital Increases for Equity Compensation Plans	For	For	Capital Management	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	28 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	29 Appointment of Auditor - Agili(3f)	For	For	Audit/Financials	Pilier Gouvernance
Abivax	FR0012333284	FR	Mix	05/06/2023	30 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	1. Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	СН	Annual	08/06/2023	Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	СН	Annual	08/06/2023	3. Ratification of Management Acts	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.a Elect Rodger Novak	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.b Elect Samarth Kulkarni	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.c Elect Ali Behbahani	Against	Against	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.d Elect Maria Fardis	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.e Elect H. Edward Fleming, Jr.	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.f Elect Simeon J. George	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	4.g Elect John T. Greene	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	СН	Annual	08/06/2023	4.h Elect Katherine A. High	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	СН	Annual	08/06/2023	4.i Elect Douglas A. Treco	Against	Against	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	5.a Elect Ali Behbahani	Against	Against	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	5.b Elect H. Edward Fleming, Jr.	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	5.c Elect Simeon J. George	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	5.d Elect John T. Greene	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	6.a Board Compensation (Fixed)	For	For	Compensation	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	6.b Board Compensation (Variable)	Against	Against	Compensation	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	6.c Executive Compensation (Fixed)	For	For	Compensation	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	6.d Executive Compensation (Short-Term Variable)	For	For	Compensation	Pilier Gouvernance

		1.							
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	6.f Swiss Statutory Compensation Report	Against	Against	Compensation	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	8. Approval of Capital Band	For	For	Capital Management	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	9. Increase in Conditional Share Capital for Employee Equity Plans	Against	Against	Capital Management	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	10. Amendment to the 2018 Stock Option and Incentive Plan	Against	Against	Compensation	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	СН	Annual	08/06/2023	11. Change in Board Size	For	For	Board Related	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	12a Amendments to Articles (Company Purpose)	For	For	Changes to Company Statutes	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	12b Amendments to Articles (General Meeting)	For	For	Changes to Company Statutes	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	12c Amendments to Articles (Jurisdiction Clause)	Against	Against	Changes to Company Statutes	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	12d Amendments to Articles (Miscellaneous)	For	For	Changes to Company Statutes	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	12e Amendments to Articles (Editorial Changes)	For	For	Changes to Company Statutes	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	13. Election of Independent Voting Rights Representative	For	For	Meeting Administration	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	14. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
CRISPR Therapeutics AG	CH0334081137	CH	Annual	08/06/2023	15. Transaction of Other Business	Against	Against	Meeting Administration	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	1.01 Elect Juan Andres	Withhold	Against	Board Related	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	1.02 Elect Julie H. McHugh	For	For	Board Related	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	1.03 Elect Robert L. Rosiello	For	For	Board Related	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	3. Amendment to the 2018 Incentive Award Plan	Against	Against	Compensation	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	4. Reverse Stock Split	For	For	Capital Management	Pilier Gouvernance
Evelo Biosciences Inc		US	Annual	08/06/2023	5. Right to Adjourn Meeting	For	For	Meeting Administration	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	1.1 Elect Richard J. Barry	Against	Against	Board Related	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	1.2 Elect M. Kathleen Behrens	For	For	Board Related	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	1.3 Elect Stephen L. Mayo	For	For	Board Related	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	1.4 Elect Claude Nicaise	For	For	Board Related	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	2. Advisory Vote on Executive Compensation	Against	Against	Compensation	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	3. Amendment to the 2018 Equity Incentive Plan	For	For	Compensation	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	4. Amendment to the 2013 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	5. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Sarepta Therapeutics Inc	US8036071004	US	Annual	08/06/2023	6. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	1a. Elect Joseph L. Goldstein	Against	Against	Board Related	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	1b. Elect Christine A. Poon	For	For	Board Related	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	1c. Elect Craig B. Thompson	For	For	Board Related	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	1d. Elect Huda Y. Zoghbi	For	For	Board Related	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Regeneron Pharmaceuticals, Inc.	US75886F1075	US	Annual	09/06/2023	Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	1.1 Elect Rahul D. Ballal	For	For	Board Related	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	1.2 Elect Brian Goff	For	For	Board Related	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	1.3 Elect Cynthia Smith	For	For	Board Related	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	3. Approval of the 2023 Stock Incentive Plan	For	For	Compensation	Pilier Gouvernance
Agios Pharmaceuticals Inc	US00847X1046	US	Annual	13/06/2023	4. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
		US	Annual		1.1 Elect Julian C. Baker	For	For	,	
Incyte Corp.	US45337C1027			14/06/2023		-		Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual Annual	14/06/2023	1.2 Elect Jean-Jacques Bienaimé	For For	For	Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US		14/06/2023	1.3 Elect Otis W. Brawley	For	For For	Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027		Annual	14/06/2023	1.4 Elect Paul J. Clancy			Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	1.5 Elect Jacqualyn A. Fouse	For	For	Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US US	Annual Annual	14/06/2023	1.6 Elect Edmund P. Harrigan	For For	For For	Board Related Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027			14/06/2023	1.7 Elect Katherine A. High				Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	1.8 Elect Hervé Hoppenot	For	For	Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	1.9 Elect Susanne Schaffert	For	For	Board Related	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	3. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	4. Amendment to the 2010 Stock Incentive Plan	For	For	Compensation	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	5. Amendment to the 1997 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Incyte Corp.	US45337C1027	US	Annual	14/06/2023	6. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Arvinas Inc	US04335A1051	US	Annual	15/06/2023	1.01 Elect Sunil Agarwal	For	For	Board Related	Pilier Gouvernance
Arvinas Inc	US04335A1051	US	Annual	15/06/2023	1.02 Elect Leslie V. Norwalk	For	For	Board Related	Pilier Gouvernance
Arvinas Inc	US04335A1051	US	Annual	15/06/2023	1.03 Elect John D. Young	For	For	Board Related	Pilier Gouvernance
Arvinas Inc	US04335A1051	US	Annual	15/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Arvinas Inc	US04335A1051	US	Annual	15/06/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017		Annual	15/06/2023	O1 Elect Margaret Han Dugan	For	For	Board Related	Pilier Gouvernance

D-:C 14-1	10/04440/4047	ку	Ammont	45 /05 /2022	CO Florida No. October	F	F	Daniel Balatad	Dilian Carrana
BeiGene Ltd BeiGene Ltd	KYG1146Y1017 KYG1146Y1017	KY	Annual Annual	15/06/2023 15/06/2023	O2 Elect John V. Oyler O3 Elect Alessandro Riva	For For	For For	Board Related Board Related	Pilier Gouvernance Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY	Annual		O4 Ratification of Auditor	For	For	Audit/Financials	
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023 15/06/2023	O5 Authority to Assign Auditor's Fees	For	For	Audit/Financials	Pilier Gouvernance Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023	O7 General Mandate to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023	O8 Connected Person Placing Authorization I	Against			
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023	O9 Connected Person Placing Authorization I	Against	Against Against	Capital Management Capital Management	Pilier Gouvernance Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY	Annual		O10 Approval of Amgen's Direct Purchase Option	_	_	-	Pilier Gouvernance
				15/06/2023	•	For	For	Capital Management	
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023	O11 Approval of Restricted Share Unit Grant to John V. Oyler	For For	For	Compensation	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017		Annual	15/06/2023	O12 Approval of Restricted Share Unit Grant to Xiaodong Wang		For	Compensation	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY	Annual	15/06/2023	O13 Approval of Restricted Share Unit Grant to Other Non-Executive and Independent Non-Executive Directors	For	For	Compensation	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017	KY KY	Annual	15/06/2023	S15 Adoption of New Articles	For	For	Changes to Company Statutes	Pilier Gouvernance
BeiGene Ltd	KYG1146Y1017		Annual	15/06/2023	O16 Approve the Adjournment of the Annual Meeting	For	For	Meeting Administration	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US		15/06/2023	1.01 Elect Michael F. Cola	For For	For	Board Related	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US	Annual	15/06/2023	1.02 Elect Barry E. Greene		For	Board Related	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US	Annual	15/06/2023	1.03 Elect Jeffrey M. Jonas	For	For	Board Related	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US	Annual Annual	15/06/2023	1.04 Elect Jessica J. Federer	For For	For	Board Related	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US		15/06/2023	2. Ratification of Auditor	-	-	Audit/Financials	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US	Annual	15/06/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Sage Therapeutics Inc	US78667J1088	US	Annual	15/06/2023	4. Amendment to the 2014 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Schrodinger Inc	US80810D1037	US	Annual	15/06/2023	1a. Elect Richard Freisner	For	For	Board Related	Pilier Gouvernance
Schrodinger Inc	US80810D1037	US	Annual	15/06/2023	1b. Elect Rosana Kapeller-Libermann	For	For	Board Related	Pilier Gouvernance
Schrodinger Inc	US80810D1037	US	Annual	15/06/2023	1c. Elect Gary Sender	For	For	Board Related	Pilier Gouvernance
Schrodinger Inc	US80810D1037	US	Annual	15/06/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Schrodinger Inc	US80810D1037	US	Annual	15/06/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	2 Consolidated Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	3 Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	4 Special Auditors Report on Regulated Agreements	Against	Against	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	5 Elect Eric Leire	Against	Against	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	6 Elect Nicolas Poirier	For	For	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	7 Elect Anne-Laure Autret-Cornet	For	For	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	8 Elect Brigitte Dreno	Against	Against	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	9 Elect Gérard Tobelem	For	For	Board Related	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	10 2023 Remuneration Policy (Executive Chair)	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	11 2023 Remuneration Policy (CEO)	For	For	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	12 2023 Remuneration Policy (Board of Directors)	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	13 2022 Remuneration Report	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	14 2022 Remuneration of Dominique Costantini, Executive Chair	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	15 2022 Remuneration of CEOs	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	16 Authority to Repurchase and Reissue Shares	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	17 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	18 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	19 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	20 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	21 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Investment Funds)	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	22 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	23 Authority to Increase Capital in Case of Exchange Offers	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	24 Authority to Set Offering Price of Shares	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	25 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	26 Global Ceiling on Capital Increases and Debt Issuances	For	For	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	27 Authority to Issue Restricted Shares	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	28 Authority to Issue Preference Shares	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	29 Authority to Grant Warrants (BSA)	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	30 Authority to Grant Warrants (BSPCE)	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	31 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	32 Global Ceiling on Capital Increases for Equity Compensation Plans	For	For	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	33 Employee Stock Purchase Plan	For	Against	Compensation	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	34 Authority to Cancel Shares and Reduce Capital	Against	Against	Capital Management	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	35 Amendments to Articles Regarding Chair Age Limits	For	For	Changes to Company Statutes	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	36 Amendments to Articles Regarding Directors Age Limits	For	For	Changes to Company Statutes	Pilier Gouvernance
OSE Immunotherapeutics	FR0012127173	FR	Mix	22/06/2023	37 Authorisation of Legal Formalities	For	For	Meeting Administration	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	1 Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance

Qiagen NV	NL0012169213	NL	Annual	22/06/2023	2 Remuneration Report	For	For	Compensation	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	3 Ratification of Management Board Acts	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	4 Ratification of Supervisory Board Acts	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.a Elect Metin Colpan	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.b Elect Toralf Haag	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.c Elect Ross L. Levine	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.d Elect Elaine Mardis	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.e Elect Eva Pisa	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.f Elect Lawrence A. Rosen	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.g Elect Stephen H. Rusckowski	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	5.h Elect Elizabeth E. Tallett	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	6.a Elect Thierry Bernard	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	6.b Elect Roland Sackers	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	7 Appointment of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	8.a Authority to Issue Shares w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	8.b Authority to Suppress Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	9 Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	10 Authorize Managing Board and De Brauw Blackstone Westbroek N.V. to Execute These Amendments	For	For	Board Related	Pilier Gouvernance
Qiagen NV	NL0012169213	NL	Annual	22/06/2023	11 Cancellation of Fractional Shares	For	For	Capital Management	Pilier Gouvernance
-		NL				For			
Qiagen NV	NL0012169213	JP	Annual	22/06/2023	12 Approval of the 2023 Stock Plan		For	Compensation	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.1 Elect Kenji Yasukawa	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007		Annual	22/06/2023	1.2 Elect Naoki Okamura	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.3 Elect Katsuyoshi Sugita	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.4 Elect Takashi Tanaka	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.5 Elect Eriko Sakurai	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.6 Elect Masahiro Miyazaki	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	1.7 Elect Yoichi Ono	For	For	Board Related	Pilier Gouvernance
Astellas Pharma Inc.	JP3942400007	JP	Annual	22/06/2023	2 Elect Rie Akiyama as Audit Committee Director	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1a. Elect Alexander J. Denner	Abstain	Against	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1b. Elect Caroline D. Dorsa	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1c. Elect Maria C. Freire	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1d. Elect William A. Hawkins	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1e. Elect William D. Jones	Abstain	Against	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1f. Elect Jesus B. Mantas	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1g. Elect Richard C. Mulligan	Abstain	Against	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1h. Elect Eric K. Rowinsky	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1i. Elect Stephen A. Sherwin	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	1j. Elect Christopher A. Viehbacher	For	For	Board Related	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	4. Frequency of Advisory Vote on Executive Compensation	1 Year	For	Compensation	Pilier Gouvernance
Biogen Inc	US09062X1037	US	Annual	26/06/2023	5. Elect Susan K. Langer	For	For	Board Related	Pilier Gouvernance
BioXcel Therapeutics Inc	US09075P1057	US	Annual	26/06/2023	1.02 Elect Michael P. Miller	For	For	Board Related	Pilier Gouvernance
BioXcel Therapeutics Inc	US09075P1057	US	Annual	26/06/2023	1.03 Elect Michal Votruba	For	For	Board Related	Pilier Gouvernance
· ·		US				For			
BioXcel Therapeutics Inc	US09075P1057	FR	Annual	26/06/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Nanobiotix	FR0011341205		Mix	27/06/2023	2 Consolidated Accounts and Reports			Audit/Financials	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	3 Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	4 Special Auditors Report on Regulated Agreements	For	For	Board Related	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	5 Elect Gary Phillips	Against	Against	Board Related	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	6 2022 Remuneration of Laurent Levy, Management Board Chair	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	7 2022 Remuneration of Anne-Juliette Hermant, Management Board Member	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	8 2022 Remuneration of Bartholomeus van Rhijn, Management Board Member	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	9 2022 Remuneration of Gary Phillips, Supervisory Board Chair	For	For	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	10 2022 Remuneration Report	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	11 2023 Remuneration Policy (Supervisory Board Members)	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	12 2023 Remuneration Policy (Laurent Levy, Management Board Chair)	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	13 2023 Remuneration Policy (Anne-Juliette Hermant, Management Board Member)	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	14 2023 Remuneration Policy (Bartholomeus van Rhijn, Management Board Member)	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	15 2023 Stock Option Plan	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	16 Authority to Repurchase and Reissue Shares	Against	Against	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	17 Authority to Cancel Shares and Reduce Capital	Against	Against	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	18 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
		1.44		,,	, , , , , , , , , , , , , , , , , , , ,		, Jan. 194	1 - 1	

								1	1
Nanobiotix Nanobiotix	FR0011341205	FR FR	Mix Mix	27/06/2023 27/06/2023	19 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
	FR0011341205	FR	Mix		20 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance Pilier Gouvernance
Nanobiotix Nanobiotix	FR0011341205 FR0011341205	FR	Mix	27/06/2023 27/06/2023	21 Authority to Set Offering Price of Shares 22 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Equity Line)	Against Against	Against Against	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	22 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Equity Line) 23 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Equity Financing Program)	Against	Against	Capital Management Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix					' '	
Nanobiotix	FR0011341205	FR	Mix	27/06/2023 27/06/2023	24 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Investment Funds) 25 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Health or Biotechnology Specialised Entities)	Against	Against Against	Capital Management Capital Management	Pilier Gouvernance Pilier Gouvernance
	FR0011341205	FR	Mix		26 Greenshoe	Against	_		
Nanobiotix		FR		27/06/2023		Against	Against	Capital Management	Pilier Gouvernance
lanobiotix	FR0011341205	FR	Mix Mix	27/06/2023	27 Authority to Increase Capital in Case of Exchange Offers	Against	Against	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205			27/06/2023	28 Authority to Increase Capital in Consideration for Contributions In Kind	Against	Against	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	29 Global Ceiling on Capital Increases and Debt Issuances	For	For	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR FR	Mix	27/06/2023	30 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	31 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205		Mix	27/06/2023	32 Authority to Issue Performance Shares	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	33 Authority to Grant Warrants	Against	Against	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	34 Global Ceiling on Capital Increases (Compensation Plans)	For	For	Capital Management	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	35 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	36 Non-Liquidation of the Company	For	For	M&A	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	2 Consolidated Accounts and Reports	For	For	Audit/Financials	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	3 Allocation of Losses	For	For	Audit/Financials	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	4 Transfer of Reserves	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	5 Special Auditors Report on Regulated Agreements	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	6 Elect Jean-Pierre Garnier	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	7 Elect Laurent Arthaud	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	8 Elect Pierre Bastid	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	9 Elect Rainer Boehm	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	10 Elect Cécile Chartier	For	For	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	11 Authority to Repurchase and Reissue Shares	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	12 Authority to Cancel Shares and Reduce Capital	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	13 Amendments to Articles Regarding Chair Age Limits	Against	Against	Changes to Company Statutes	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	14 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Banque Européenne d'Investissement - BEI)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	15 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Qualified Investors)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	16 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Underwriters - At the Market)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	17 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Biotechnology Companies)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	18 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights (Qualified Investors - Financing Agreement)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	19 Authority to Issue Shares w/o Preemptive Rights (American Market Financing Program - ATM)	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	20 Authority to Issue Shares and Convertible Debt w/ Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	21 Authority to Issue Shares and Convertible Debt w/o Preemptive Rights	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	22 Authority to Issue Shares and Convertible Debt Through Private Placement	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	23 Greenshoe	Against	Against	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	24 Global Ceiling on Capital Increases and Debt Issuances	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	25 Authority to Increase Capital Through Capitalisations	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	26 Authority to Grant Stock Options	Against	Against	Compensation	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	27 Authority to Issue Performance Shares	Against	Against	Compensation	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	28 Global Ceiling on Capital Increases for Equity Compensation Plans	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	27/06/2023	29 Employee Stock Purchase Plan	For	Against	Compensation	Pilier Gouvernance
Terumo Corporation	JP3546800008	JP	Annual	27/06/2023	1 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	2 Amendments to Articles	For	For	Changes to Company Statutes	Pilier Gouvernance
Terumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.1 Elect Toshiaki Takagi	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.2 Elect Shinjiro Sato	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.3 Elect Shoji Hatano	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.4 Elect Kazunori Hirose	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.5 Elect Norimasa Kunimoto	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.6 Elect Yukiko Kuroda @ Yukiko Matsumoto	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.7 Elect Hidenori Nishi	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	3.8 Elect Keiya Ozawa	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	4.1 Elect Takanori Shibazaki	Against	Against	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	4.2 Elect Masaichi Nakamura	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	4.3 Elect Soichiro Uno	For	For	Board Related	Pilier Gouvernance
erumo Corporation	JP3546800008	JP	Annual	27/06/2023	5 Elect Koichi Sakaguchi as Alternate Audit Committee Director	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	1 Allocation of Profits/Dividends	For	For	Audit/Financials	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.1 Elect Shigenobu Maekawa	For	For	Board Related	Pilier Gouvernance

Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.2 Elect Toru Nakai	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.3 Elect Shozo Sano	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.4 Elect Takashi Takaya	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.5 Elect Takanori Edamitsu	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.6 Elect Kazuchika Takagaki	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.7 Elect Hitoshi Ishizawa	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.8 Elect Hitomi Kimura	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.9 Elect Miyuki Sakurai	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.10 Elect Yoshinao Wada	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.11 Elect Yukari Kobayashi	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	2.12 Elect Mayumi Nishi	For	For	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	3.1 Elect Hirotsugu Ito	Against	Against	Board Related	Pilier Gouvernance
Nippon Shinyaku Co. Ltd.	JP3717600005	JP	Annual	29/06/2023	3.2 Elect Hiroharu Hara	For	For	Board Related	Pilier Gouvernance
Replimune Group Inc	US76029N1063	US	Annual	06/09/2023	1.1 Elect Paolo Pucci	Withhold	Against	Board Related	Pilier Gouvernance
		US							
Replimune Group Inc	US76029N1063		Annual	06/09/2023	1.2 Elect Veleka Peeples-Dyer	For	For	Board Related	Pilier Gouvernance
Replimune Group Inc	US76029N1063	US	Annual	06/09/2023	2. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Special	15/09/2023	1 Dividend in Kind to Effect Spin-Off of Sandoz Group AG	For	For	Audit/Financials	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Special	15/09/2023	2 Amendment to Par Value	For	For	Capital Management	Pilier Gouvernance
Novartis AG	CH0012005267	CH	Special	15/09/2023	3 Additional or Amended Proposals	Against		Meeting Administration	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1a. Elect Craig Arnold	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1b. Elect Scott C. Donnelly	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1c. Elect Lidia L. Fonseca	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1d. Elect Andrea J. Goldsmith	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1e. Elect Randall J. Hogan, III	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1f. Elect Gregory P. Lewis	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1g. Elect Kevin E. Lofton	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1h. Elect Geoffrey Straub Martha	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1i. Elect Elizabeth G. Nabel	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1j. Elect Denise M. O'Leary	For	For	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	1k. Elect Kendall J. Powell	Against	Against	Board Related	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	2. Appointment of Auditor and Authority to Set Fees	For	For	Audit/Financials	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	3. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	4. Approval of the 2024 Employee Stock Purchase Plan	For	For	Compensation	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	5. Authority to Issue Shares w/ Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Medtronic Plc	IE00BTN1Y115	IE	Annual	19/10/2023	6. Authority to Issue Shares w/o Preemptive Rights	For	For	Capital Management	Pilier Gouvernance
Medtronic Plc	IEOOBTN1Y115	IE	Annual	19/10/2023	7. Authority to Repurchase Shares	For	For	Capital Management	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Special	13/12/2023	Bristol-Myers Transaction	For	For	M&A	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Special	13/12/2023	2. Advisory Vote on Golden Parachutes	Against	Against	Compensation	Pilier Gouvernance
Mirati Therapeutics Inc	US60468T1051	US	Special	13/12/2023	3. Right to Adjourn Meeting	For	For	Meeting Administration	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1A. Elect W. Don Cornwell	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1B. Elect JoEllen Lyons Dillon	Against	Against	Board Related	Pilier Gouvernance
					·				
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1C. Elect Elisha W. Finney	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1D. Elect Leo Groothuis	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1E. Elect Melina E. Higgins	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1F. Elect James M. Kilts	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1G. Elect Harry A. Korman	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1H. Elect Rajiv Malik	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	11. Elect Richard A. Mark	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1J. Elect Mark W. Parrish	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	1K. Elect Scott A. Smith	For	For	Board Related	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	2. Advisory Vote on Executive Compensation	For	For	Compensation	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	3. Ratification of Auditor	For	For	Audit/Financials	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	4. Amendment to the Certificate of Incorporation Regarding Forum Provision	Against	Against	Changes to Company Statutes	Pilier Gouvernance
Viatris Inc	US92556V1061	US	Annual	15/12/2023	5. Amendment to Articles Regarding Officer Exculpation	Against	Against	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	22/12/2023	2 Issuance of Shares w/o Preemptive Rights (AstraZeneca Holdings B.V.)	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	22/12/2023	3 Creation of a New Category of Preference Shares (B Shares)	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	22/12/2023	4 Authority to Issue Preference Shares (AstraZeneca Holdings B.V.)	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	22/12/2023	5 Suppression of Preemptive rights (AstraZeneca Holdings B.V.)	For	For	Capital Management	Pilier Gouvernance
Cellectis	FR0010425595	FR	Mix	22/12/2023	6 Employee Stock Purchase Plan	For	Against	Compensation	Pilier Gouvernance
		FR	Mix	22/12/2023	7 Elect AstraZeneca Holdings B.V. (Marc Dunoyer)	Against	Against	Board Related	Pilier Gouvernance
Cellectis	FR0010425595	FK							
Cellectis Cellectis	FR0010425595 FR0010425595	FR	Mix	22/12/2023	8 Elect AstraZeneca Holdings B.V. (Tyrell J. Rivers)	For	For	Board Related	Pilier Gouvernance

Astrazeneca plc	GB0009895292	GB	Annual	27/04/2023	7 Authorisation of Political Donations	For	For	Other	Autre
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	17 Authorisation of Political Donations	For	For	Other	Autre
GSK Plc	GB00BN7SWP63	GB	Annual	03/05/2023	22 Approve Exemption from Statement of the Senior Statutory Auditor's name in published Auditors' Reports	For	For	Other	Autre
Nanobiotix	FR0011341205	FR	Mix	27/06/2023	37 Acknowledgment of the Company's Financial Situation	Against	Against	Other	Autre

NOVARTIS AG

ISIN CH0012005267 Meeting Date 07-Mar-23

Country Switzerland

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For
2	Ratification of Board and Management Acts	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Cancellation of Shares and Reduction in Share Capital	Management	For	For	For
5	Authority to Repurchase Shares	Management	For	For	For
6.1	Amendments to Articles (Virtual General Meetings)	Management	For	For	For
6.2	Amendments to Articles (Miscellaneous)	Management	For	For	For
6.3	Amendments to Articles (Alignment with Law)	Management	For	For	For
7.1	Board Compensation	Management	For	For	For
7.2	Executive Compensation	Management	For	For	For
7.3	Compensation Report	Management	For	For	For
8.1	Elect Jörg Reinhardt as Board Chair	Management	For	For	For
8.2	Elect Nancy C. Andrews	Management	For	For	For
8.3	Elect Ton Büchner	Management	For	For	For
8.4	Elect Patrice Bula	Management	For	For	For
8.5	Elect Elizabeth Doherty	Management	For	For	For
8.6	Elect Bridgette P. Heller	Management	For	For	For
8.7	Elect Daniel Hochstrasser	Management	For	For	For
8.8	Elect Frans van Houten	Management	For	For	For
8.9	Elect Simon Moroney	Management	For	For	For
8.10	Elect Ana de Pro Gonzalo	Management	For	For	For
8.11	Elect Charles L. Sawyers	Management	For	For	For

21-Feb-24 1 of 140

8.12	Elect William T. Winters	Management	For	For	For
8.13	Elect John D. Young	Management	For	For	For
9.1	Elect Patrice Bula as Compensation Committee Member	Management	For	For	For
9.2	Elect Bridgette P. Heller as Compensation Committee	Management	For	For	For
9.3	Elect Simon Moroney as Compensation Committee Chair	Management	For	For	For
9.4	Elect William T. Winters as Compensation Committee	Management	For	For	For
10	Appointment of Auditor	Management	For	For	For
11	Appointment of Independent Proxy	Management	For	For	For
В	Transaction of Other Business	Management		Against	N/A

DEMANT AS

ISIN	DK0060738599	Meeting Date	08-Mar-23	
ntry	Denmark			

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2	Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Remuneration Report	Management	For	For	For
5	Directors' Fees	Management	For	For	For
6.A	Elect Niels Bjørn Christiansen	Management	For	Abstain	Against
6.B	Elect Niels Jacobsen	Management	For	For	For
6.C	Elect Anja Madsen	Management	For	Abstain	Against
6.D	Elect Sisse Fjelsted Rasmussen	Management	For	Abstain	Against
6.E	Elect Kristian Villumsen	Management	For	For	For

21-Feb-24 2 of 140

7	Appointment of Auditor	Management	For	For	For
8.A	Authority to reduce share capital	Management	For	For	For
8.B	Authority to Repurchase Shares	Management	For	For	For
8.C	Authorization of Legal Formalities	Management	For	For	For

NOVO NORDISK

ISIN DK0060534915 Meeting Date 23-Mar-23

Country Denmark

Proposal Number	Durange	Dunnament	Marrie Don	Vote	For/Agains
	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2	Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Remuneration Report	Management	For	For	For
5.1	Directors' Fees 2022	Management	For	For	For
5.2	Directors' Fees 2023	Management	For	For	For
5.3	Amendments to Remuneration Policy	Management	For	For	For
6.1	Elect Helge Lund as Chair	Management	For	For	For
6.2	Elect Henrik Poulsen as Vice Chair	Management	For	For	For
6.3.A	Elect Laurence Debroux	Management	For	For	For
6.3.B	Elect Andreas Fibig	Management	For	For	For
6.3.C	Elect Sylvie Grégoire	Management	For	For	For
6.3.D	Elect Kasim Kutay	Management	For	For	For
6.3.E	Elect Christina Choi Lai Law	Management	For	For	For
6.3.F	Elect Martin Mackay	Management	For	Abstain	Against

21-Feb-24 3 of 140

7.1	Appointment of Auditor	Management	For	For	For
8.1	Cancellation of Shares	Management	For	For	For
8.2	Authority to Repurchase Shares	Management	For	For	For
8.3	Authority to Issue Shares w/ or w/o Preemptive Rights	Management	For	For	For
8.4	Shareholder Proposal Regarding Company's Product	Shareholder	Against	Against	For

SARTORIUS STEDIM BIOTECH S.A.

ISIN FR0013154002 Meeting Date 27-Mar-23

Country France

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Ratification of Acts; Non Tax-	Management	For	Against	Against
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Special Auditors Report on Regulated Agreements	Management	For	Against	Against
5	2023 Remuneration Policy (Board of Directors)	Management	For	For	For
6	2022 Remuneration Report	Management	For	Against	Against
7	2022 Remuneration of Joachim Kreuzburg, Chair and CEO	Management	For	Against	Against
8	2023 Remuneration Policy (Chair and CEO)	Management	For	For	For
9	2022 Remuneration of René Faber, Deputy CEO	Management	For	Against	Against
10	2023 Remuneration Policy (Deputy CEO)	Management	For	For	For
11	Authority to Repurchase and Reissue Shares	Management	For	For	For
12	Authorisation of Legal Formalities	Management	For	For	For

21-Feb-24 4 of 140

13	Authority to Issue Shares w/o Preemptive Rights (Unicorn-	Management	For	For	For
14	Authority to Cancel Shares and Reduce Capital	Management	For	For	For
15	Employee Stock Purchase Plan	Management	For	Against	Against
16	Authorisation of Legal Formalities	Management	For	For	For

GENMAB

ISIN DK0010272202 Meeting Date 29-Mar-23

Country Denmark

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
2	Accounts and Reports; Ratification of Board and	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Remuneration Report	Management	For	For	For
5.A	Elect Deirdre P. Connelly	Management	For	For	For
5.B	Elect Pernille Erenbjerg	Management	For	For	For
5.C	Elect Rolf Hoffman	Management	For	For	For
5.D	Elect Elizabeth O'Farrell	Management	For	For	For
5.E	Elect Paolo Paoletti	Management	For	For	For
5.F	Elect Anders Gersel Pedersen	Management	For	For	For
6	Appointment of Auditor	Management	For	For	For
7.A	Directors' Fees	Management	For	For	For
7.B	Amendment to Remuneration Policy (Removal of Nominal	Management	For	For	For
7.C	Amendments to Remuneration Policy (Other Changes)	Management	For	For	For
7.D	Authority to Repurchase Shares	Management	For	For	For

21-Feb-24 5 of 140

8 Authorization of Legal Formalities Management For For For

BAVARIAN NORDIC A/S

ISIN DK0015998017 Meeting Date 30-Mar-23

Country Denmark

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2	Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Remuneration Report	Management	For	For	For
5	Ratification of Board and Management Acts	Management	For	For	For
6.01	Elect Anders Gersel Pedersen	Management	For	For	For
6.02	Elect Peter Kürstein	Management	For	For	For
6.03	Elect Frank Verwiel	Management	For	For	For
6.04	Elect Anne Louise Eberhard	Management	For	For	For
6.05	Elect Luc Debruyne	Management	For	For	For
6.06	Elect Heidi Hunter	Management	For	For	For
6.07	Elect Johan Van Hoof	Management	For	For	For
7.01	Appointment of Auditor	Management	For	For	For
8A	Authority to Issue Shares w/ or w/o Preemptive Rights	Management	For	For	For
8B	Authority to Issue Convertible Debt Instruments	Management	For	Against	Against
8C	Issuance of Warrants w/o Preemptive Rights	Management	For	For	For
8D	Amendments to Remuneration Policy	Management	For	For	For

21-Feb-24 6 of 140

8E	Directors' Fees	Management	For	Against	Against
8F	Authority to Repurchase Shares	Management	For	For	For
8G	Amendments to Articles	Management	For	For	For

STELLANTIS N.V

ISIN NL00150001Q9 Meeting Date 13-Apr-23

Country Netherlands

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2.c	Remuneration Report Excluding Pre-Merger Legacy	Management	For	Against	Against
2.d	Remuneration Report (Pre-Merger Legacy Matter)	Management	For	Against	Against
2.e	Accounts and Reports	Management	For	For	For
2.f	Allocation of Dividends	Management	For	For	For
2.g	Ratification of Board Acts	Management	For	Against	Against
3.	Elect Benoît Ribadeau-Dumas to the Board of Directors	Management	For	Against	Against
4.a	Appointment of Auditor (FY2023)	Management	For	For	For
4.b	Appointment of Auditor (FY2024)	Management	For	For	For
5.	Remuneration Policy	Management	For	For	For
6.a	Authority to Issue Shares w/ Preemptive Rights	Management	For	Against	Against
6.b	Authority to Suppress Preemptive Rights	Management	For	Against	Against
7.	Authority to Repurchase Shares	Management	For	Against	Against
8.	Cancellation of Shares	Management	For	For	For

21-Feb-24 7 of 140

GALAPAGOS NV

ISIN BE0003818359 Meeting Date 25-Apr-23

Country Belgium

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2.	Accounts and Reports; Allocation of Losses	Management	For	For	For
5.	Remuneration Report	Management	For	Against	Against
6.	Ratification of Board of Directors, Former Supervisory	Management	For	For	For
7.	Authority to Set Auditor's Fees	Management	For	For	For
8.	Appointment of Auditor and Authority to Set Fees	Management	For	For	For
9.	Elect Peter Guenter to the Board of Directors	Management	For	For	For
10.	Elect Daniel P. O'Day to the Board of Directors	Management	For	For	For
11.	Elect Linda Higgins to the Board of Directors	Management	For	For	For

BASILEA PHARMACEUTICA AG

ISIN CH0011432447 Meeting Date 26-Apr-23

Country Switzerland

21-Feb-24 8 of 140

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1	Accounts and Reports	Management	For	For	For
2	Allocation of Profits	Management	For	For	For
3	Ratification of Board and Management Acts	Management	For	Against	Against
4.1	Appoint Domenico Scala as Board Chair	Management	For	For	For
4.2	Elect Leonard Kruimer	Management	For	For	For
4.3	Elect Martin Nicklasson	Management	For	For	For
4.4	Elect Nicole Onetto	Management	For	For	For
4.5	Elect Dr. Carole Sable	Management	For	For	For
4.6	Elect Thomas Werner	Management	For	For	For
5.1	Elect Martin Nicklasson as Compensation Committee	Management	For	For	For
5.2	Elect Nicole Onetto as Compensation Committee Member	Management	For	For	For
5.3	Elect Thomas Werner as Compensation Committee	Management	For	For	For
6.1	Board Compensation	Management	For	For	For
6.2	Executive Compensation	Management	For	For	For
6.3	Compensation Report	Management	For	Against	Against
7.1	Amendments to Articles (Shares)	Management	For	For	For
7.2	Amendments to Articles (Hybrid Meetings)	Management	For	For	For
7.3	Amendments to Articles (Miscellaneous)	Management	For	For	For
7.4	Change of Company Headquarters	Management	For	For	For
7.5	Amendments to Articles (Company Purpose)	Management	For	For	For
8	Approval of a Capital Band	Management	For	For	For
9	Appointment of Independent Proxy	Management	For	For	For
10	Appointment of Auditor	Management	For	For	For

21-Feb-24 9 of 140

JOHNSON & JOHNSON

ISIN US4781601046 Meeting Date 27-Apr-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Darius Adamczyk	Management	For	For	For
1b.	Elect Mary C. Beckerle	Management	For	For	For
1c.	Elect D. Scott Davis	Management	For	For	For
1d.	Elect Jennifer A. Doudna	Management	For	For	For
1e.	Elect Joaquin Duato	Management	For	For	For
1f.	Elect Marillyn A. Hewson	Management	For	For	For
1g.	Elect Paula A. Johnson	Management	For	For	For
1h.	Elect Hubert Joly	Management	For	For	For
11.	Elect Mark B. McClellan	Management	For	For	For
1j.	Elect Anne Mulcahy	Management	For	For	For
1k.	Elect Mark A. Weinberger	Management	For	For	For
11.	Elect Nadja Y. West	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For
5.	Shareholder Proposal Regarding Adoption of Mandatory	Shareholder	Against	Abstain	N/A
6.	Shareholder Proposal Regarding Report on Access to	Shareholder	Against	Against	For
7.	Shareholder Proposal Prohibiting Adjustments for Legal	Shareholder	Against	Abstain	N/A
8.	Shareholder Proposal Regarding Extended Patent	Shareholder	Against	Against	For

21-Feb-24 10 of 140

PFIZER INC.

ISIN US7170811035 Meeting Date 27-Apr-23

Country United States

Proposal Number	Barranal	D	Marrie Dan	W-t-	For/Agains
	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Ronald E. Blaylock	Management	For	For	For
1b.	Elect Albert Bourla	Management	For	For	For
1c.	Elect Susan Desmond-Hellmann	Management	For	For	For
1d.	Elect Joseph J. Echevarria	Management	For	For	For
1e.	Elect Scott Gottlieb	Management	For	For	For
1f.	Elect Helen H. Hobbs	Management	For	For	For
1g.	Elect Susan Hockfield	Management	For	For	For
1h.	Elect Dan R. Littman	Management	For	For	For
1i.	Elect Shantanu Narayen	Management	For	For	For
1j.	Elect Suzanne Nora Johnson	Management	For	For	For
1k.	Elect James Quincey	Management	For	For	For
11.	Elect James C. Smith	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
5.	Shareholder Proposal Regarding Severance Approval	Shareholder	Against	Against	For
6.	Shareholder Proposal Regarding Independent Chair	Shareholder	Against	For	Against

21-Feb-24 11 of 140

7.	Shareholder Proposal Regarding Intellectual Property	Shareholder	Against	Against	For
8.	Shareholder Proposal Regarding Extended Patent	Shareholder	Against	Against	For
9.	Shareholder Proposal Regarding Report on Political	Shareholder	Against	Against	For

INTUITIVE SURGICAL INC

ISIN US46120E6023 Meeting Date 27-Apr-23

Country United States

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1a.	Elect Craig H. Barratt	Management	For	For	For
1b.	Elect Joseph C. Beery	Management	For	For	For
1c.	Elect Gary S. Guthart	Management	For	For	For
1d.	Elect Amal M. Johnson	Management	For	For	For
1e.	Elect Don R. Kania	Management	For	For	For
1f.	Elect Amy L. Ladd	Management	For	For	For
1g.	Elect Keith R. Leonard, Jr.	Management	For	For	For
1h.	Elect Alan J. Levy	Management	For	For	For
1i.	Elect Jami Dover Nachtsheim	Management	For	For	For
1j.	Elect Monica P. Reed	Management	For	For	For
1k.	Elect Mark J. Rubash	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For
5.	Shareholder Proposal Regarding Median Gender and	Shareholder	Against	Against	For

21-Feb-24 12 of 140

UCB SA

ISIN BE0003739530 Meeting Date 27-Apr-23

Country Belgium

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
4.	Accounts and Reports; Allocation of Dividends	Management	For	For	For
5.	Remuneration Report	Management	For	For	For
6.	Ratification of Board Acts	Management	For	For	For
7.	Ratification of Auditor's Acts	Management	For	For	For
8.1.A	Elect Jan Berger to the Board of Directors	Management	For	For	For
8.1.B	Ratification of Independence of Jan Berger	Management	For	For	For
8.2.	Elect Cyril Janssen to the Board of Directors	Management	For	For	For
8.3.A	Elect Maëlys Castella to the Board of Directors	Management	For	For	For
8.3.B	Ratification of Independence of Maëlys Castella	Management	For	For	For
9.	Long Term Incentive Plan (Free Allocation of Shares)	Management	For	For	For
10.1	Change in Control Clause (EMTN Program)	Management	For	For	For
10.2	Change in Control Clause (European Investment Bank	Management	For	For	For
10.3	Change in Control Clause (Term Facility Agreement)	Management	For	For	For

21-Feb-24 13 of 140

ASTRAZENECA PLC

ISIN GB0009895292 Meeting Date 27-Apr-23

Country United Kingdom

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For
2	Final Dividend	Management	For	For	For
3	Appointment of Auditor	Management	For	For	For
4	Authority to Set Auditor's Fees	Management	For	For	For
5A	Elect Michel Demaré	Management	For	For	For
5B	Elect Pascal Soriot	Management	For	For	For
5C	Elect Aradhana Sarin	Management	For	For	For
5D	Elect Philip Broadley	Management	For	For	For
5E	Elect Euan Ashley	Management	For	For	For
5F	Elect Deborah DiSanzo	Management	For	For	For
5G	Elect Diana Layfield	Management	For	For	For
5H	Elect Sherilyn S. McCoy	Management	For	For	For
51	Elect Tony MOK Shu Kam	Management	For	For	For
5J	Elect Nazneen Rahman	Management	For	For	For
5K	Elect Andreas Rummelt	Management	For	For	For
5L	Elect Marcus Wallenberg	Management	For	For	For
6	Remuneration Report	Management	For	For	For
7	Authorisation of Political Donations	Management	For	For	For
8	Authority to Issue Shares w/ Preemptive Rights	Management	For	For	For
9	Authority to Issue Shares w/o Preemptive Rights	Management	For	For	For
10	Authority to Issue Shares w/o Preemptive Rights (Specified	Management	For	For	For
11	Authority to Repurchase Shares	Management	For	For	For
12	Authority to Set General Meeting Notice Period at 14 Days	Management	For	For	For

21-Feb-24 14 of 140

13 Adoption of New Articles Management For For For

ABBOTT LABORATORIES

ISIN US0028241000 Meeting Date 28-Apr-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Robert J. Alpern	Management	For	For	For
1b.	Elect Claire Babineaux-Fontenot	Management	For	For	For
1c.	Elect Sally E. Blount	Management	For	For	For
1d.	Elect Robert B. Ford	Management	For	For	For
1e.	Elect Paola Gonzalez	Management	For	For	For
1f.	Elect Michelle A. Kumbier	Management	For	For	For
1g.	Elect Darren W. McDew	Management	For	For	For
1h.	Elect Nancy McKinstry	Management	For	Against	Against
1i.	Elect Michael G. O'Grady	Management	For	For	For
1j.	Elect Michael F. Roman	Management	For	For	For
1k.	Elect Daniel J. Starks	Management	For	For	For
11.	Elect John G. Stratton	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
5.	Shareholder Proposal Regarding Right to Call Special	Shareholder	Against	Against	For

21-Feb-24 15 of 140

6.	Shareholder Proposal Regarding Independent Chair	Shareholder	Against	For	Against
7.	Shareholder Proposal Regarding Lobbying Report	Shareholder	Against	For	Against
8.	Shareholder Proposal Prohibiting Adjustments for Legal	Shareholder	Against	For	Against

BAXTER INTERNATIONAL INC.

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect José E. Almeida	Management	For	For	For
1b.	Elect Michael F. Mahoney	Management	For	For	For
1c.	Elect Patricia Morrison	Management	For	For	For
1d.	Elect Stephen N. Oesterle	Management	For	For	For
1e.	Elect Nancy M. Schlichting	Management	For	For	For
1f.	Elect Brent Shafer	Management	For	For	For
1g.	Elect Catherine R. Smith	Management	For	Against	Against
1h.	Elect Amy M. Wendell	Management	For	For	For
1i.	Elect David S. Wilkes	Management	For	For	For
1j.	Elect Peter M. Wilver	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against

21-Feb-24 16 of 140

3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For
5.	Shareholder Proposal Regarding Severance Approval	Shareholder	Against	Against	For
6.	Shareholder Proposal Regarding Retention of Shares Until	Shareholder	Against	Against	For

BRISTOL-MYERS SQUIBB CO.

ISIN US1101221083 Meeting Date 02-May-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1A.	Elect Peter J. Arduini	Management	For	For	For
1B.	Elect Deepak L. Bhatt	Management	For	For	For
1C.	Elect Giovanni Caforio	Management	For	For	For
1D.	Elect Julia A. Haller	Management	For	For	For
1E.	Elect Manuel Hidalgo Medina	Management	For	For	For
1F.	Elect Paula A. Price	Management	For	For	For
1G.	Elect Derica W. Rice	Management	For	For	For
1H.	Elect Theodore R. Samuels, II	Management	For	For	For
11.	Elect Gerald Storch	Management	For	For	For
1J.	Elect Karen H. Vousden	Management	For	For	For
1K.	Elect Phyllis R. Yale	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For

21-Feb-24 17 of 140

4.	Ratification of Auditor	Management	For	For	For
5.	Shareholder Proposal Regarding Independent Chair	Shareholder	Against	For	Against
6.	Shareholder Proposal Regarding Non-Discrimination Audit	Shareholder	Against	Against	For
7.	Shareholder Proposal Regarding Allowing Beneficial	Shareholder	Against	Against	For

ARGENX SE

ISIN NL0010832176 Meeting Date 02-May-23

Country Belgium

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
3.	Remuneration Report	Management	For	Against	Against
4.b.	Accounts and Reports	Management	For	For	For
4.d.	Allocation of Losses	Management	For	For	For
4.e.	Ratification of Board Acts	Management	For	For	For
5.	Elect Joseph Donald deBethizy to the Board of Directors	Management	For	For	For
6.	Authority to Issue Shares w/ or w/o Preemptive Rights	Management	For	For	For
7.	Appointment of Auditor	Management	For	For	For

21-Feb-24 18 of 140

MODERNA INC

ISIN US60770K1079 Meeting Date 03-May-23

Country United States

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1.1	Elect Stephen Berenson	Management	For	For	For
1.2	Elect Sandra J. Horning	Management	For	For	For
1.3	Elect Paul Sagan	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against
3.	Ratification of Auditor	Management	For	For	For
4.	Shareholder Proposal Regarding Intellectual Property	Shareholder	Against	Against	For

GILEAD SCIENCES, INC.

ISIN US3755581036 Meeting Date 03-May-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Jacqueline K. Barton	Management	For	For	For
1b.	Elect Jeffrey A. Bluestone	Management	For	For	For
1c.	Elect Sandra J. Horning	Management	For	For	For
1d.	Elect Kelly A. Kramer	Management	For	For	For
1e.	Elect Kevin E. Lofton	Management	For	For	For

21-Feb-24 19 of 140

1f.	Elect Harish Manwani	Management	For	For	For
1g.	Elect Daniel P. O'Day	Management	For	For	For
1h.	Elect Javier J. Rodriguez	Management	For	For	For
1i.	Elect Anthony Welters	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
5.	Amendment to the Employee Stock Purchase Plan	Management	For	For	For
6.	Shareholder Proposal Regarding Multiple Board Nominees	Shareholder	Against	Against	For
7.	Shareholder Proposal Regarding Allowing Beneficial	Shareholder	Against	Against	For
8.	Shareholder Proposal Regarding Extended Patent	Shareholder	Against	Against	For

GSK PLC

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For
2	Remuneration Report	Management	For	For	For
3	Elect Julie Brown	Management	For	For	For
4	Elect Vishal Sikka	Management	For	For	For
5	Elect Elizabeth McKee Anderson	Management	For	For	For
6	Elect Sir Jonathan R. Symonds	Management	For	For	For
7	Elect Emma N. Walmsley	Management	For	For	For

21-Feb-24 20 of 140

	8	Elect Charles A. Bancroft	Management	For	For	For
	9	Elect Hal V. Barron	Management	For	For	For
	10	Elect Anne Beal	Management	For	For	For
	11	Elect Harry Dietz	Management	For	For	For
	12	Elect Jesse Goodman	Management	For	For	For
	13	Elect Urs Rohner	Management	For	For	For
	14	Appointment of Auditor	Management	For	For	For
	15	Authority to Set Auditor's Fees	Management	For	For	For
	16	Amendment to Remuneration Policy	Management	For	For	For
	17	Authorisation of Political Donations	Management	For	For	For
	18	Authority to Issue Shares w/ Preemptive Rights	Management	For	For	For
	19	Authority to Issue Shares w/o Preemptive Rights	Management	For	For	For
:	20	Authority to Issue Shares w/o Preemptive Rights (Specified	Management	For	For	For
:	21	Authority to Repurchase Shares	Management	For	For	For
:	22	Approve Exemption from Statement of the Senior Statutory	Management	For	For	For
:	23	Authority to Set General Meeting Notice Period at 14 Days	Management	For	For	For

BOSTON SCIENTIFIC CORP.

ISIN US1011371077 Meeting Date 04-May-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Nelda J. Connors	Management	For	For	For
1b.	Elect Charles J. Dockendorff	Management	For	For	For

21-Feb-24 21 of 140

1c.	Elect Yoshiaki Fujimori	Management	For	For	For
1d.	Elect Edward J. Ludwig	Management	For	For	For
1e.	Elect Michael F. Mahoney	Management	For	For	For
1f.	Elect David J. Roux	Management	For	For	For
1g.	Elect John E. Sununu	Management	For	For	For
1h.	Elect David S. Wichmann	Management	For	For	For
1i.	Elect Ellen M. Zane	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For

IDORSIA LTD

ISIN	CH0363463438	Meeting Date	04-May-23
Country	Switzerland		

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1.1	Accounts and Reports	Management	For	For	For
1.2	Compensation Report	Management	For	Against	Against
2	Allocation of Losses	Management	For	For	For
3	Ratification of Board and Management Acts	Management	For	For	For
4.1.1	Elect Mathieu Simon	Management	For	For	For
4.1.2	Elect Joern Aldag	Management	For	For	For
4.1.3	Elect Jean-Paul Clozel	Management	For	For	For

21-Feb-24 22 of 140

4.1.4	Elect Felix R. Ehrat	Management	For	For	For
4.1.5	Elect Srishti Gupta	Management	For	For	For
4.1.6	Elect Peter N. Kellogg	Management	For	For	For
4.1.7	Elect Sandy Mahatme	Management	For	For	For
4.1.8	Elect Sophie Kornowski	Management	For	For	For
4.2	Appoint Mathieu Simon as Board Chair	Management	For	For	For
4.3.1	Elect Felix R. Ehrat	Management	For	For	For
4.3.2	Elect Srishti Gupta	Management	For	For	For
4.3.3	Elect Mathieu Simon	Management	For	For	For
4.3.4	Elect Sophie Kornowski-Bonnet	Management	For	For	For
5.1	Board Compensation	Management	For	For	For
5.2	Executive Compensation	Management	For	For	For
6	Appointment of Independent Proxy	Management	For	For	For
7	Appointment of Auditor	Management	For	For	For
8.1	Amendments to Articles	Management	For	For	For
8.2	Authority to Issue Convertible Debt Instruments; Increase in	Management	For	Against	Against
8.3	Capital Band	Management	For	Against	Against
8.4	Amendments to Articles (Cap on Dilutive Issuances)	Management	For	For	For
8.5	Amendments to Articles (Miscellaneous)	Management	For	For	For
8.6	Amendments to Articles (Various)	Management	For	For	For

HALOZYME THERAPEUTICS INC.

ISIN	US40637H1095	Meeting Date	05-May-23
------	--------------	--------------	-----------

Country United States

21-Feb-24 23 of 140

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1A.	Elect Bernadette Connaughton	Management	For	For	For
1B.	Elect Moni Miyashita	Management	For	For	For
1C.	Elect Matthew L. Posard	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For

ABBVIE INC

ISIN US00287Y1091 Meeting Date 05-May-23
Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Robert J. Alpern	Management	For	For	For
1b.	Elect Melody B. Meyer	Management	For	For	For
1c.	Elect Frederick H. Waddell	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Elimination of Supermajority Requirement	Management	For	For	For
5.	Shareholder Proposal Regarding Simple Majority Vote	Shareholder	Against	Against	For
6.	Shareholder Proposal Regarding Report on Political	Shareholder	Against	Against	For
7.	Shareholder Proposal Regarding Lobbying Report	Shareholder	Against	Against	For

21-Feb-24 24 of 140

8. Shareholder Proposal Regarding Extended Patent Shareholder Against Against For

ALCON INC.

ISIN CH0432492467 Meeting Date 05-May-23

Country Switzerland

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For
2	Ratification of Board and Management Acts	Management	For	For	For
3	Allocation of Dividends	Management	For	For	For
4.1	Compensation Report	Management	For	For	For
4.2	Board Compensation	Management	For	For	For
4.3	Executive Compensation	Management	For	For	For
5.1	Elect F. Michael Ball as Chair	Management	For	For	For
5.2	Elect Lynn Dorsey Bleil	Management	For	For	For
5.3	Elect Raquel C. Bono	Management	For	For	For
5.4	Elect Arthur Cummings	Management	For	For	For
5.5	Elect David J. Endicott	Management	For	For	For
5.6	Elect Thomas Glanzmann	Management	For	For	For
5.7	Elect D. Keith Grossman	Management	For	For	For
5.8	Elect Scott H. Maw	Management	For	For	For
5.9	Elect Karen J. May	Management	For	For	For
5.10	Elect Ines Pöschel	Management	For	For	For
5.11	Elect Dieter Spälti	Management	For	For	For

21-Feb-24 25 of 140

6.1	Elect Thomas Glanzmann as Compensation Committee	Management	For	For	For
6.2	Elect Scott H. Maw as Compensation Committee Member	Management	For	For	For
6.3	Elect Karen J. May as Compensation Committee Member	Management	For	For	For
6.4	Elect Ines Pöschel as Compensation Committee Member	Management	For	For	For
7	Appointment of Independent Proxy	Management	For	For	For
8	Appointment of Auditor	Management	For	For	For
9.1	Introduction of a Capital Band	Management	For	For	For
9.2	Increase in Conditional Capital	Management	For	For	For
9.3	Amendments to Articles (Share Capital)	Management	For	For	For
9.4	Amendments to Articles (Shareholder Meetings)	Management	For	For	For
9.5	Amendments to Articles (Board of Directors)	Management	For	For	For
9.6	Amendments to Articles (Compensation)	Management	For	For	For

MIRATI THERAPEUTICS INC

ISIN	US60468T1051	Meeting Date	11-May-23
Country	United States		

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Charles M. Baum	Management	For	For	For
1.2	Elect Bruce L.A. Carter	Management	For	For	For
1.3	Elect Julie Cherrington	Management	For	For	For
1.4	Elect Aaron Davis	Management	For	For	For
1.5	Elect Faheem Hasnain	Management	For	Withhold	Against

21-Feb-24 26 of 140

1.6	Elect Craig A. Johnson	Management	For	For	For
1.7	Elect Maya Martinez-Davis	Management	For	For	For
1.8	Elect David Meek	Management	For	For	For
1.9	Elect Shalini Sharp	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against
3.	Ratification of Auditor	Management	For	For	For
4.	Amendment to the 2013 Employee Stock Purchase Plan	Management	For	For	For

HUTCHMED (CHINA) LIMITED

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.	Accounts and Reports	Management	For	For	For
2A.	Elect Simon TO Chi Keung	Management	For	Against	Against
2B.	Elect Weiguo SU	Management	For	For	For
2C.	Elect Johnny CHENG Chig Fung	Management	For	For	For
2D.	Elect Dan Eldar	Management	For	For	For
2E.	Elect Edith SHIH	Management	For	For	For
2F.	Elect Lefei SUN	Management	For	For	For
2G.	Elect Paul R. Carter	Management	For	For	For
2H.	Elect Graeme A. Jack	Management	For	Against	Against

21-Feb-24 27 of 140

21.	Elect Tony MOK Shu Kam	Management	For	For	For
3.	Appointment of Auditor and Authority to Set Fees	Management	For	For	For
4.	Authority to Issue Shares w/o Preemptive Rights	Management	For	For	For
5.	Authority to Repurchase Shares	Management	For	For	For

INNATE PHARMA

ISIN FR0010331421 Meeting Date 12-May-23

Country France

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses;	Management	For	Against	Against
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Losses	Management	For	For	For
4	Special Auditors Report On Regulated Agreements	Management	For	For	For
5	Elect Irina Staatz-Granzer	Management	For	Against	Against
6	Elect Véronique Chabernaud	Management	For	Against	Against
7	Elect Olivier Martinez	Management	For	For	For
8	Elect Jean-Yves Blay	Management	For	Against	Against
9	Elect Gilles Brisson	Management	For	Against	Against

21-Feb-24 28 of 140

10	Elect Hervé Brailly	Management	For	For	For
11	2023 Supervisory Board Members' Fees	Management	For	Against	Against
12	2023 Remuneration Policy (Executives)	Management	For	Against	Against
13	2023 Remuneration Policy (Management Board Chair)	Management	For	For	For
14	2023 Remuneration Policy (Management Board Members)	Management	For	For	For
15	2023 Remuneration Policy (Supervisory Board Chair)	Management	For	For	For
16	2023 Remuneration Policy (Supervisory Board Members)	Management	For	Against	Against
17	2022 Remuneration Report	Management	For	Against	Against
18	2022 Remuneration of Mondher Majoubi, Management	Management	For	Against	Against
	Brand Obate	· ·		J	· ·
19	2022 Remuneration of Yannis Morel, Management Board	Management	For	Against	Against
			_	_	_
20	2022 Remuneration of Hervé Brailly, Supervisory Board	Management	For	For -	For
21	Authority to Repurchase and Reissue Shares	Management	For	For	For
22	Authority to Issue Shares and Convertible Debt w/	Management	For	For	For
23	Authority to Issue Shares w/o Preemptive Rights	Management	For	Against	Against
24	Authority to Issue Shares Through Private Placement	Management	For	Against	Against
	·	· ·		· ·	Ū
25	Authority to Set Offering Price of Shares	Management	For	Against	Against
26	Authority to Issue Shares and Convertible Debt w/o	Managament	For	Against	Against
26	Authority to Issue Shares and Convertible Debt w/o	Management	FOI	Against	Against
27	Authority to Issue Shares In the Form of ADS w/o	Management	For	Against	Against
	December District /ATM December				

21-Feb-24 29 of 140

28	Greenshoe	Management	For	Against	Against
29	Authority to Increase Capital in Consideration for	Management	For	Against	Against
30	Authority to Increase Capital in Case of Exchange Offers	Management	For	For	For
31	Global Ceiling on Capital Increases	Management	For	For	For
32	Authority to Issue Performance Shares to (Executives)	Management	For	For	For
33	Authority to Issue Performance Shares to (Employees)	Management	For	For	For
34	Authority to Issue Restricted Shares	Management	For	For	For
35	Employee Stock Purchase Plan	Management	For	For	For
36	Authority to Grant Warrants (Supervisory Board Members)	Management	For	Against	Against
37	Authority to Cancel Shares and Reduce Capital	Management	For	Against	Against
38	Authorisation of Legal Formalities	Management	For	For	For

VERTEX PHARMACEUTICALS, INC.

ISIN US92532F1003 Meeting Date 17-May-23
Country United States

Proposal For/Agains Number Proposal Proponent Mgmt Rec Vote Mgmt For Elect Sangeeta N. Bhatia Management For For 1.1 1.2 Elect Lloyd A. Carney Management For For For

21-Feb-24 30 of 140

1.3	Elect Alan M. Garber	Management	For	For	For
1.4	Elect Terrence C. Kearney	Management	For	For	For
1.5	Elect Reshma Kewalramani	Management	For	For	For
1.6	Elect Jeffrey M. Leiden	Management	For	For	For
1.7	Elect Diana L. McKenzie	Management	For	For	For
1.8	Elect Bruce I. Sachs	Management	For	For	For
1.9	Elect Suketu Upadhyay	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For

NEUROCRINE BIOSCIENCES, INC.

ISIN	US64125C1099	Meeting Date	17-May-23

Country United States

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1.1	Elect Kevin C. Gorman	Management	For	For	For
1.2	Elect Gary Lyons	Management	For	For	For
1.3	Elect Johanna Mercier	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Amendment to the 2020 Equity Incentive Plan	Management	For	For	For
5.	Ratification of Auditor	Management	For	For	For

21-Feb-24 31 of 140

MORPHOSYS AG

ISIN DE0006632003 Meeting Date 17-May-23

Country Germany

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
2	Ratification of Management Board Acts	Management	For	For	For
3	Ratification of Supervisory Board Acts	Management	For	For	For
4	Appointment of Auditor	Management	For	For	For
5.1	Elect Michael L. Brosnan	Management	For	For	For
5.2	Elect George Golumbeski	Management	For	For	For
6	Increase in Authorised Capital I	Management	For	For	For
7	Increase in Authorised Capital II	Management	For	For	For
8	Cancellation of Authorised Capital	Management	For	For	For
9	Remuneration Report	Management	For	For	For
10.1	Amendments to Articles (Virtual Meetings)	Management	For	For	For
10.2	Amendments to Articles (Virtual AGM Participation of	Management	For	Against	Against

ALNYLAM PHARMACEUTICALS INC

ISIN US02043Q1076 Meeting Date 18-May-23

21-Feb-24 32 of 140

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Michael W. Bonney	Management	For	For	For
1b.	Elect Yvonne Greenstreet	Management	For	For	For
1c.	Elect Phillip A. Sharp	Management	For	For	For
1d.	Elect Elliott Sigal	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For

AMGEN INC.

ISIN US0311622098 Meeting Date 19-May-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Wanda M. Austin	Management	For	For	For
1b.	Elect Robert A. Bradway	Management	For	For	For
1c.	Elect Michael V. Drake	Management	For	For	For
1d.	Elect Brian J. Druker	Management	For	For	For
1e.	Elect Robert A. Eckert	Management	For	For	For
1f.	Elect Greg C. Garland	Management	For	For	For
1g.	Elect Charles M. Holley, Jr.	Management	For	For	For

21-Feb-24 33 of 140

1h.	Elect S. Omar Ishrak	Management	For	For	For
1i.	Elect Tyler Jacks	Management	For	For	For
1j.	Elect Ellen J. Kullman	Management	For	For	For
1k.	Elect Amy E. Miles	Management	For	For	For
11.	Elect Ronald D. Sugar	Management	For	For	For
1m.	Elect R. Sanders Williams	Management	For	For	For
2.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Ratification of Auditor	Management	For	For	For

MERCK & CO INC

ISIN	US58933Y1055	Meeti	ng Date	23-May-23
Country	United States			

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Douglas M. Baker, Jr.	Management	For	For	For
1b.	Elect Mary Ellen Coe	Management	For	For	For
1c.	Elect Pamela J. Craig	Management	For	For	For
1d.	Elect Robert M. Davis	Management	For	For	For
1e.	Elect Thomas H. Glocer	Management	For	For	For
1f.	Elect Risa Lavizzo-Mourey	Management	For	For	For
1g.	Elect Stephen L. Mayo	Management	For	For	For
1h.	Elect Paul B. Rothman	Management	For	For	For
1i.	Elect Patricia F. Russo	Management	For	For	For

21-Feb-24 34 of 140

1j.	Elect Christine E. Seidman	Management	For	For	For
1k.	Elect Inge G. Thulin	Management	For	For	For
11.	Elect Kathy J. Warden	Management	For	For	For
1m.	Elect Peter C. Wendell	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For
5.	Shareholder Proposal Regarding Report on Corporate	Shareholder	Against	Against	For
6.	Shareholder Proposal Regarding Report on Access to	Shareholder	Against	Against	For
7.	Shareholder Proposal Regarding Third-Party Political	Shareholder	Against	Against	For
8.	Shareholder Proposal Regarding Extended Patent	Shareholder	Against	Against	For
9.	Shareholder Proposal Regarding Congruency Report of	Shareholder	Against	Against	For
10.	Shareholder Proposal Regarding Independent Chair	Shareholder	Against	For	Against

BIOMERIEUX

ISIN	FR0013280286	Meeting Date	23-May-23
Country	France		

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Ratification of Board Acts	Management	For	Against	Against

21-Feb-24 35 of 140

4	Allocation of Profits/Dividends	Management	For	For	For
5	Related Party Transactions (Fondation Christophe and	Management	For	For	For
6	Related Party Transactions (Specific Diagnostics)	Management	For	For	For
7	Elect Philippe Archinard	Management	For	Against	Against
8	Appointment of Auditor (Grant Thornton)	Management	For	For	For
9	2023 Remuneration Policy (Corporate Officers)	Management	For	Against	Against
10	2023 Remuneration Policy (Chair and CEO)	Management	For	For	For
11	2023 Remuneration Policy (Deputy CEO)	Management	For	Against	Against
12	2023 Remuneration Policy (Board of Directors)	Management	For	For	For
13	2022 Remuneration Report	Management	For	For	For
14	2022 Remuneration of Alexandre Merieux, Chair and CEO	Management	For	For	For
15	2022 Remuneration of Pierre Boulud, Deputy CEO	Management	For	Against	Against
16	Authority to Repurchase and Reissue Shares	Management	For	For	For
17	Authority to Cancel Shares and Reduce Capital	Management	For	For	For
18	Authority to Issue Shares and Convertible Debt w/	Management	For	Against	Against
19	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
			_		
20	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
24	Authority to Set Offering Dries of Shares	Managament	For	Against	Against
21	Authority to Set Offering Price of Shares	Management	FOI	Against	Against
22	Greenshoe	Management	For	Against	Against
	C. 53.13.135			34	. 19411131
23	Authority to Increase Capital in Consideration for	Management	For	Against	Against
	O	3		J	.334

21-Feb-24 36 of 140

Authority to Issue Shares w/o Preemptive Rights in	Management	For	Against	Against
Authority to Grant Stock Options	Management	For	Against	Against
Employee Stock Purchase Plan	Management	For	For	For
Removal of Preemptive Rights Rights in Favour of	Management	For	For	For
Global Ceiling on Capital Increases and Debt Issuances	Management	For	For	For
Acknowledgement of the Non-Conversion to a Corporate	Management	For	For	For
Authorisation of Legal Formalities	Management	For	For	For
	Global Ceiling on Capital Increases and Debt Issuances Acknowledgement of the Non-Conversion to a Corporate	Employee Stock Purchase Plan Removal of Preemptive Rights Rights in Favour of Global Ceiling on Capital Increases and Debt Issuances Acknowledgement of the Non-Conversion to a Corporate Management Management	Authority to Grant Stock Options Management For Employee Stock Purchase Plan Removal of Preemptive Rights Rights in Favour of Global Ceiling on Capital Increases and Debt Issuances Management For Acknowledgement of the Non-Conversion to a Corporate Management For	Authority to Grant Stock Options Management For Against Employee Stock Purchase Plan Removal of Preemptive Rights Rights in Favour of Global Ceiling on Capital Increases and Debt Issuances Management For For Acknowledgement of the Non-Conversion to a Corporate Management For For For For For

THERMO FISHER SCIENTIFIC INC.

ISIN US8835561023 Meeting Date 24-May-23
Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Marc N. Casper	Management	For	For	For
1b.	Elect Nelson J. Chai	Management	For	For	For
1c.	Elect Ruby R. Chandy	Management	For	For	For
1d.	Elect C. Martin Harris	Management	For	For	For
1e.	Elect Tyler Jacks	Management	For	For	For
1f.	Elect R. Alexandra Keith	Management	For	For	For
1g.	Elect James C. Mullen	Management	For	For	For

21-Feb-24 37 of 140

1h.	Elect Lars R. Sørensen	Management	For	For	For
1i.	Elect Debora L. Spar	Management	For	For	For
1j.	Elect Scott M. Sperling	Management	For	For	For
1k.	Elect Dion J. Weisler	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Ratification of Auditor	Management	For	For	For
5.	Amendment to the 2013 Stock Incentive Plan	Management	For	For	For
6.	Approval of the 2023 Employee Stock Purchase Plan	Management	For	For	For

SANOFI

ISIN	FR0000120578	Meeting Date	25-May-23
Country	France		

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Elect Frédéric Oudéa	Management	For	For	For
5	2022 Remuneration Report	Management	For	For	For
6	2022 Remuneration of Serge Weinberg, Chair	Management	For	Against	Against
7	2022 Remuneration of Paul Hudson, CEO	Management	For	Against	Against

21-Feb-24 38 of 140

8	2023 Directors' Fees	Management	For	Against	Against
9	2023 Remuneration Policy (Board of Directors)	Management	For	Against	Against
10	2023 Remuneration Policy (Chair)	Management	For	Against	Against
11	2023 Remuneration Policy (CEO)	Management	For	For	For
12	Appointment of Auditor (PwC)	Management	For	Against	Against
13	Relocation of Corporate Headquarters	Management	For	For	For
14	Authority to Repurchase and Reissue Shares	Management	For	For	For
15	Authority to Cancel Shares and Reduce Capital	Management	For	For	For
16	Authority to Issue Shares and Convertible Debt w/	Management	For	For	For
17	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
18	Authority to Issue Shares and/or Convertible Debt Through	Management	For	Against	Against
19	Authority to Issue Debt Instruments	Management	For	For	For
20	Greenshoe	Management	For	Against	Against
21	Authority to Increase Capital in Consideration for	Management	For	Against	Against
22	Authority to Increase Capital Through Capitalisations	Management	For	For	For
23	Employee Stock Purchase Plan	Management	For	For	For
24	Authorisation of Legal Formalities	Management	For	For	For

21-Feb-24 39 of 140

RELAY THERAPEUTICS INC

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Douglas S. Ingram	Management	For	For	For
1.2	Elect Sekar Kathiresan	Management	For	For	For
1.3	Elect Jami Rubin	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against
3.	Ratification of Auditor	Management	For	For	For

IPSEN

ISIN FR0010259150 Meeting Date 31-May-23

Country France

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Profits/Dividends	Management	For	For	For
4	Special Auditors Report on Regulated Agreements	Management	For	For	For
5	Appointment of Auditor (KPMG)	Management	For	Against	Against

21-Feb-24 40 of 140

6	Elect Marc de Garidel	Management	For	Against	Against
7	Elect Henri Beaufour	Management	For	Against	Against
8	Elect Michèle Ollier	Management	For	Against	Against
9	2023 Remuneration Policy (Board of Directors)	Management	For	For	For
10	2023 Remuneration Policy (Chair)	Management	For	For	For
11	2023 Remuneration Policy (CEO and Other Executives)	Management	For	For	For
12	2022 Remuneration Report	Management	For	Against	Against
13	2022 Remuneration of Marc de Garidel, Chair	Management	For	Against	Against
14	2022 Remuneration of David Loew, CEO	Management	For	For	For
15	Authority to Repurchase and Reissue Shares	Management	For	For	For
16	Authority to Cancel Shares and Reduce Capital	Management	For	For	For
17	Authority to Increase Capital Through Capitalisations	Management	For	For	For
18	Authority to Issue Shares and Convertible Debt w/	Management	For	For	For
19	Authority to Increase Capital in Case of Exchange Offers	Management	For	Against	Against
20	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
21	Greenshoe	Management	For	Against	Against
22	Authority to Increase Capital in Consideration for	Management	For	Against	Against
23	Employee Stock Purchase Plan	Management	For	For	For
24	Authority to Grant Stock Options	Management	For	Against	Against

21-Feb-24 41 of 140

25	Amendments to Articles Regarding Chair Age Limits	Management	For	For	For
26	Amendments to Articles Regarding Board Meetings'	Management	For	For	For
27	Authorisation of Legal Formalities	Management	For	For	For

SANGAMO THERAPEUTICS INC

ISIN US8006771062 Meeting Date 01-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Courtney Beers	Management	For	For	For
1.2	Elect Robert F. Carey	Management	For	For	For
1.3	Elect Kenneth J. Hillan	Management	For	Against	Against
1.4	Elect Margaret A. Horn	Management	For	For	For
1.5	Elect Alexander D. Macrae	Management	For	For	For
1.6	Elect John H. Markels	Management	For	For	For
1.7	Elect James R. Meyers	Management	For	For	For
1.8	Elect H. Stewart Parker	Management	For	For	For
1.9	Elect Karen L. Smith	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Amendment to the 2018 Equity Incentive Plan	Management	For	For	For
5.	Increase in Authorized Common Stock	Management	For	For	For

21-Feb-24 42 of 140

6.	Amendment to Articles to Reflect New Delaware Law	Management	For	Against	Against
7.	Ratification of Auditor	Management	For	For	For

EDITAS MEDICINE INC

ISIN US28106W1036 Meeting Date 01-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Bernadette Connaughton	Management	For	For	For
1.2	Elect Elliott Levy	Management	For	For	For
1.3	Elect Akshay K. Vaishnaw	Management	For	Withhold	Against
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Ratification of Auditor	Management	For	For	For

IONIS PHARMACEUTICALS INC

ISIN US4622221004 Meeting Date 01-Jun-23

Country United States

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1.1	Elect Spencer R. Berthelsen	Management	For	For	For
1.2	Elect Joan E. Herman	Management	For	For	For
1.3	Elect B. Lynne Parshall	Management	For	For	For
1.4	Elect Joseph H. Wender	Management	For	Withhold	Against
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Amendment to the 2011 Equity Incentive Plan	Management	For	For	For
5.	Amendment to the 2002 Non-Employee Directors' Stock	Management	For	For	For
6.	Ratification of Auditor	Management	For	For	For

ABIVAX

ISIN	FR0012333284	Meeting Date	05-Jun-23
Country	France		

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Allocation of Losses	Management	For	For	For
3	Special Auditors Report on Regulated Agreements	Management	For	For	For
4	Ratification of Co-option of Marc de Garidel	Management	For	For	For
5	2022 Remuneration Report	Management	For	For	For
6	2022 Remuneration of Philippe Pouletty, Former Chair	Management	For	For	For

21-Feb-24 44 of 140

7	2022 Remuneration of Corinna zur Bonsen-Thomas, Chair	Management	For	For	For
8	2022 Remuneration of Hartmut Ehrlich, CEO	Management	For	Against	Against
9	2023 Remuneration Policy (Chair)	Management	For	For	For
10	2023 Remuneration Policy (CEO)	Management	For	Against	Against
11	2023 Remuneration Policy (Board of Directors)	Management	For	Against	Against
12	Authority to Repurchase and Reissue Shares	Management	For	Against	Against
13	Authority to Cancel Shares and Reduce Capital	Management	For	Against	Against
14	Authority to Issue Shares and Convertible Debt w/	Management	For	Against	Against
15	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
16	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
17	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
18	Authority to Set Offering Price of Shares	Management	For	Against	Against
19	Greenshoe	Management	For	Against	Against
20	Authority to Increase Capital Through Capitalisations	Management	For	For	For
21	Authority to Increase Capital in Consideration for	Management	For	Against	Against
22	Authority to Increase Capital in Case of Exchange Offers	Management	For	Against	Against

21-Feb-24 45 of 140

23	Global Ceiling on Capital Increases and Debt Issuances	Management	For	For	For
24	Authority to Grant Stock Options	Management	For	Against	Against
25	Authority to Grant Warrants	Management	For	Against	Against
26	Authority to Issue Restricted Shares	Management	For	Against	Against
27	Global Ceiling on Capital Increases for Equity	Management	For	For	For
28	Employee Stock Purchase Plan	Management	For	For	For
29	Appointment of Auditor - Agili(3f)	Management	For	For	For
30	Authorisation of Legal Formalities	Management	For	For	For

SAREPTA THERAPEUTICS INC

 ISIN
 US8036071004
 Meeting Date
 08-Jun-23

 Country
 United States

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1.1	Elect Richard J. Barry	Management	For	Against	Against
1.2	Elect M. Kathleen Behrens	Management	For	For	For
1.3	Elect Stephen L. Mayo	Management	For	For	For
1.4	Elect Claude Nicaise	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	Against	Against

21-Feb-24 46 of 140

3.	Amendment to the 2018 Equity Incentive Plan	Management	For	For	For
4.	Amendment to the 2013 Employee Stock Purchase Plan	Management	For	For	For
5.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
6.	Ratification of Auditor	Management	For	For	For

EVELO BIOSCIENCES INC

ISIN Meeting Date 08-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Juan Andres	Management	For	Withhold	Against
1.2	Elect Julie H. McHugh	Management	For	For	For
1.3	Elect Robert L. Rosiello	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Amendment to the 2018 Incentive Award Plan	Management	For	Against	Against
4.	Reverse Stock Split	Management	For	For	For
5.	Right to Adjourn Meeting	Management	For	For	For

21-Feb-24 47 of 140

CRISPR THERAPEUTICS AG

ISIN CH0334081137 Meeting Date 08-Jun-23

Country Switzerland

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.	Accounts and Reports	Management	For	For	For
2.	Allocation of Profits/Dividends	Management	For	For	For
3.	Ratification of Management Acts	Management	For	For	For
4.a	Elect Rodger Novak	Management	For	For	For
4.b	Elect Samarth Kulkarni	Management	For	For	For
4.c	Elect Ali Behbahani	Management	For	Against	Against
4.d	Elect Maria Fardis	Management	For	For	For
4.e	Elect H. Edward Fleming, Jr.	Management	For	For	For
4.f	Elect Simeon J. George	Management	For	For	For
4.g	Elect John T. Greene	Management	For	For	For
4.h	Elect Katherine A. High	Management	For	For	For
4.i	Elect Douglas A. Treco	Management	For	Against	Against
5.a	Elect Ali Behbahani	Management	For	Against	Against
5.b	Elect H. Edward Fleming, Jr.	Management	For	For	For
5.c	Elect Simeon J. George	Management	For	For	For
5.d	Elect John T. Greene	Management	For	For	For
6.a	Board Compensation (Fixed)	Management	For	For	For
6.b	Board Compensation (Variable)	Management	For	Against	Against
6.c	Executive Compensation (Fixed)	Management	For	For	For

21-Feb-24 48 of 140

6.d	Executive Compensation (Short-Term Variable)	Management	For	For	For
6.e	Executive Compensation (Long-Term Variable)	Management	For	Against	Against
6.f	Swiss Statutory Compensation Report	Management	For	Against	Against
7.	Advisory Vote on Executive Compensation	Management	For	Against	Against
8.	Approval of Capital Band	Management	For	For	For
9.	Increase in Conditional Share Capital for Employee Equity	Management	For	Against	Against
10.	Amendment to the 2018 Stock Option and Incentive Plan	Management	For	Against	Against
11.	Change in Board Size	Management	For	For	For
12a	Amendments to Articles (Company Purpose)	Management	For	For	For
12b	Amendments to Articles (General Meeting)	Management	For	For	For
12c	Amendments to Articles (Jurisdiction Clause)	Management	For	Against	Against
12d	Amendments to Articles (Miscellaneous)	Management	For	For	For
12e	Amendments to Articles (Editorial Changes)	Management	For	For	For
13.	Election of Independent Voting Rights Representative	Management	For	For	For
14.	Ratification of Auditor	Management	For	For	For
15.	Transaction of Other Business	Management	For	Against	Against

REGENERON PHARMACEUTICALS, INC.

ISIN	US75886F1075	Meeting Date	09-Jun-23	

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Joseph L. Goldstein	Management	For	Against	Against
1b.	Elect Christine A. Poon	Management	For	For	For
1c.	Elect Craig B. Thompson	Management	For	For	For
1d.	Elect Huda Y. Zoghbi	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
5.	Shareholder Proposal Regarding Extended Patent	Shareholder	Against	Against	For

AGIOS PHARMACEUTICALS INC

ISIN US00847X1046 Meeting Date 13-Jun-23
Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Rahul D. Ballal	Management	For	For	For
1.2	Elect Brian Goff	Management	For	For	For
1.3	Elect Cynthia Smith	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Approval of the 2023 Stock Incentive Plan	Management	For	For	For

21-Feb-24 50 of 140

4. Ratification of Auditor Management For For For

INCYTE CORP.

ISIN US45337C1027 Meeting Date 14-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Julian C. Baker	Management	For	For	For
1.2	Elect Jean-Jacques Bienaimé	Management	For	For	For
1.3	Elect Otis W. Brawley	Management	For	For	For
1.4	Elect Paul J. Clancy	Management	For	For	For
1.5	Elect Jacqualyn A. Fouse	Management	For	For	For
1.6	Elect Edmund P. Harrigan	Management	For	For	For
1.7	Elect Katherine A. High	Management	For	For	For
1.8	Elect Hervé Hoppenot	Management	For	For	For
1.9	Elect Susanne Schaffert	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For
4.	Amendment to the 2010 Stock Incentive Plan	Management	For	For	For
5.	Amendment to the 1997 Employee Stock Purchase Plan	Management	For	For	For
6.	Ratification of Auditor	Management	For	For	For

21-Feb-24 51 of 140

BIOGEN INC

ISIN US09062X1037 Meeting Date 14-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Alexander J. Denner	Management	for	Abstain	Against
1b.	Elect Caroline D. Dorsa	Management	For	For	For
1c.	Elect Maria C. Freire	Management	For	For	For
1d.	Elect William A. Hawkins	Management	For	For	For
1e.	Elect William D. Jones	Management	for	Abstain	Against
1f.	Elect Jesus B. Mantas	Management	For	For	For
1g.	Elect Richard C. Mulligan	Management	for	Abstain	Against
1h.	Elect Eric K. Rowinsky	Management	For	For	For
1i.	Elect Stephen A. Sherwin	Management	For	For	For
1j.	Elect Christopher A. Viehbacher	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Frequency of Advisory Vote on Executive Compensation	Management	1 Year	1 Year	For

SAGE THERAPEUTICS INC

21-Feb-24 52 of 140

ISIN US78667J1088 **Meeting Date** 15-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Michael F. Cola	Management	For	For	For
1.2	Elect Barry E. Greene	Management	For	For	For
1.3	Elect Jeffrey M. Jonas	Management	For	For	For
1.4	Elect Jessica J. Federer	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Amendment to the 2014 Employee Stock Purchase Plan	Management	For	For	For

ARVINAS INC

ISIN US04335A1051 Meeting Date 15-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Sunil Agarwal	Management	For	For	For
1.2	Elect Leslie V. Norwalk	Management	For	For	For
1.3	Elect John D. Young	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Ratification of Auditor	Management	For	For	For

21-Feb-24 53 of 140

SCHRODINGER INC

ISIN US80810D1037 **Meeting Date** 15-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1a.	Elect Richard Freisner	Management	For	For	For
1b.	Elect Rosana Kapeller-Libermann	Management	For	For	For
1c.	Elect Gary Sender	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Ratification of Auditor	Management	For	For	For

BEIGENE LTD

ISIN KYG1146Y1017 Meeting Date 15-Jun-23

Country Cayman Islands

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
01	Elect Margaret Han Dugan	Management	For	For	For
O2	Elect John V. Oyler	Management	For	For	For
O3	Elect Alessandro Riva	Management	For	For	For

21-Feb-24 54 of 140

O4	Ratification of Auditor	Management	For	For	For
O5	Authority to Assign Auditor's Fees	Management	For	For	For
O6	Approval of a Share Issue Mandate	Management	For	Against	Against
07	General Mandate to Repurchase Shares	Management	For	For	For
08	Connected Person Placing Authorization I	Management	For	Against	Against
O9	Connected Person Placing Authorization II	Management	For	Against	Against
O10	Approval of Amgen's Direct Purchase Option	Management	For	For	For
O11	Approval of Restricted Share Unit Grant to John V. Oyler	Management	For	For	For
012	Approval of Restricted Share Unit Grant to Xiaodong Wang	Management	For	For	For
O13	Approval of Restricted Share Unit Grant to Other Non-	Management	For	For	For
O14	Advisory Vote on Executive Compensation	Management	For	Against	Against
S15	Adoption of New Articles	Management	For	For	For
O16	Approve the Adjournment of the Annual Meeting	Management	For	For	For

QIAGEN NV

ISIN NL0012169213 Meeting Date 22-Jun-23
Country Netherlands

Proposal				F	or/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports	Management	For	For	For

21-Feb-24 55 of 140

2	Remuneration Report	Management	For	For	For
3	Ratification of Management Board Acts	Management	For	For	For
4	Ratification of Supervisory Board Acts	Management	For	For	For
5.a	Elect Metin Colpan	Management	For	For	For
5.b	Elect Toralf Haag	Management	For	For	For
5.c	Elect Ross L. Levine	Management	For	For	For
5.d	Elect Elaine Mardis	Management	For	For	For
5.e	Elect Eva Pisa	Management	For	For	For
5.f	Elect Lawrence A. Rosen	Management	For	For	For
5.g	Elect Stephen H. Rusckowski	Management	For	For	For
5.h	Elect Elizabeth E. Tallett	Management	For	For	For
6.a	Elect Thierry Bernard	Management	For	For	For
6.b	Elect Roland Sackers	Management	For	For	For
7	Appointment of Auditor	Management	For	For	For
8.a	Authority to Issue Shares w/ Preemptive Rights	Management	For	Against	Against
			_	_	_
8.b	Authority to Suppress Preemptive Rights	Management	For	For	For
9	Authority to Repurchase Shares	Management	For	For	For
10	Authorize Managing Board and De Brauw Blackstone	Management	For	For	For
11	Cancellation of Fractional Shares	Management	For	For	For
12	Approval of the 2023 Stock Plan	Management	For	For	For

OSE IMMUNOTHERAPEUTICS

ISIN FR0012127173	Meeting Date	22-Jun-23
--------------------------	--------------	-----------

Country France

21-Feb-24 56 of 140

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Losses	Management	For	For	For
4	Special Auditors Report on Regulated Agreements	Management	For	Against	Against
5	Elect Eric Leire	Management	For	Against	Against
6	Elect Nicolas Poirier	Management	For	For	For
7	Elect Anne-Laure Autret-Cornet	Management	For	For	For
8	Elect Brigitte Dreno	Management	For	Against	Against
9	Elect Gérard Tobelem	Management	For	For	For
10	2023 Remuneration Policy (Executive Chair)	Management	For	Against	Against
11	2023 Remuneration Policy (CEO)	Management	For	For	For
12	2023 Remuneration Policy (Board of Directors)	Management	For	Against	Against
13	2022 Remuneration Report	Management	For	Against	Against
14	2022 Remuneration of Dominique Costantini, Executive	Management	For	Against	Against
15	2022 Remuneration of CEOs	Management	For	Against	Against
16	Authority to Repurchase and Reissue Shares	Management	For	Against	Against
17	Authority to Increase Capital Through Capitalisations	Management	For	For	For
18	Authority to Issue Shares and Convertible Debt w/	Management	For	Against	Against

21-Feb-24 57 of 140

19	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
20	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
21	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
22	Authority to Increase Capital in Consideration for	Management	For	Against	Against
23	Authority to Increase Capital in Case of Exchange Offers	Management	For	Against	Against
24	Authority to Set Offering Price of Shares	Management	For	Against	Against
25	Greenshoe	Management	For	Against	Against
26	Global Ceiling on Capital Increases and Debt Issuances	Management	For	For	For
27	Authority to Issue Restricted Shares	Management	For	Against	Against
28	Authority to Issue Preference Shares	Management	For	Against	Against
29	Authority to Grant Warrants (BSA)	Management	For	Against	Against
30	Authority to Grant Warrants (BSPCE)	Management	For	Against	Against
31	Authority to Grant Stock Options	Management	For	Against	Against
32	Global Ceiling on Capital Increases for Equity	Management	For	For	For
33	Êmployee Stock Purchase Plan	Management	Against	For	Against
34	Authority to Cancel Shares and Reduce Capital	Management	For	Against	Against

21-Feb-24 58 of 140

35	Amendments to Articles Regarding Chair Age Limits	Management	For	For	For
36	Amendments to Articles Regarding Directors Age Limits	Management	For	For	For
37	Authorisation of Legal Formalities	Management	For	For	For

ASTELLAS PHARMA INC.

ISIN JP3942400007 Meeting Date 22-Jun-23

Country Japan

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Kenji Yasukawa	Management	For	For	For
1.2	Elect Naoki Okamura	Management	For	For	For
1.3	Elect Katsuyoshi Sugita	Management	For	For	For
1.4	Elect Takashi Tanaka	Management	For	For	For
1.5	Elect Eriko Sakurai	Management	For	For	For
1.6	Elect Masahiro Miyazaki	Management	For	For	For
1.7	Elect Yoichi Ono	Management	For	For	For
2	Elect Rie Akiyama as Audit Committee Director	Management	For	For	For

BIOXCEL THERAPEUTICS INC

21-Feb-24 59 of 140

ISIN US09075P1057 **Meeting Date** 26-Jun-23

Country United States

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Sandeep Laumas	Management	For	Withhold	Against
1.2	Elect Michael P. Miller	Management	For	For	For
1.3	Elect Michal Votruba	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For

NANOBIOTIX

ISIN FR0011341205 Meeting Date 27-Jun-23

Country France

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Losses	Management	For	For	For
4	Special Auditors Report on Regulated Agreements	Management	For	For	For
5	Elect Gary Phillips	Management	For	Against	Against
6	2022 Remuneration of Laurent Levy, Management Board	Management	For	Against	Against
7	2022 Remuneration of Anne-Juliette Hermant,	Management	For	Against	Against
8	2022 Remuneration of Bartholomeus van Rhijn,	Management	For	Against	Against

21-Feb-24 60 of 140

9	2022 Remuneration of Gary Phillips, Supervisory Board	Management	For	For	For
10	2022 Remuneration Report	Management	For	Against	Against
11	2023 Remuneration Policy (Supervisory Board Members)	Management	For	Against	Against
12	2023 Remuneration Policy (Laurent Levy, Management	Management	For	Against	Against
13	2023 Remuneration Policy (Anne-Juliette Hermant,	Management	For	Against	Against
14	2023 Remuneration Policy (Bartholomeus van Rhijn,	Management	For	Against	Against
15	2023 Stock Option Plan	Management	For	Against	Against
16	Authority to Repurchase and Reissue Shares	Management	For	Against	Against
17	Authority to Cancel Shares and Reduce Capital	Management	For	Against	Against
18	Authority to Issue Shares and Convertible Debt w/	Management	For	Against	Against
19	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
20	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
21	Authority to Set Offering Price of Shares	Management	For	Against	Against
22	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
23	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
24	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
25	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
26	Greenshoe	Management	For	Against	Against
27	Authority to Increase Capital in Case of Exchange Offers	Management	For	Against	Against
28	Authority to Increase Capital in Consideration for	Management	For	Against	Against
29	Global Ceiling on Capital Increases and Debt Issuances	Management	For	For	For
30	Authority to Increase Capital Through Capitalisations	Management	For	For	For
31	Authority to Grant Stock Options	Management	For	Against	Against
32	Authority to Issue Performance Shares	Management	For	Against	Against
33	Authority to Grant Warrants	Management	For	Against	Against
34	Global Ceiling on Capital Increases (Compensation Plans)	Management	For	For	For
35	Employee Stock Purchase Plan	Management	For	For	For
36	Non-Liquidation of the Company	Management	For	For	For
37	Acknowledgment of the Company's Financial Situation	Management	For	Against	Against

21-Feb-24 61 of 140

CELLECTIS

ISIN FR0010425595 Meeting Date 27-Jun-23

Country France

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Accounts and Reports; Non Tax-Deductible Expenses	Management	For	For	For
2	Consolidated Accounts and Reports	Management	For	For	For
3	Allocation of Losses	Management	For	For	For
4	Transfer of Reserves	Management	For	For	For
5	Special Auditors Report on Regulated Agreements	Management	For	For	For
6	Elect Jean-Pierre Garnier	Management	For	For	For
7	Elect Laurent Arthaud	Management	For	For	For
8	Elect Pierre Bastid	Management	For	For	For
9	Elect Rainer Boehm	Management	For	For	For
10	Elect Cécile Chartier	Management	For	For	For
11	Authority to Repurchase and Reissue Shares	Management	For	Against	Against
12	Authority to Cancel Shares and Reduce Capital	Management	For	Against	Against
13	Amendments to Articles Regarding Chair Age Limits	Management	For	Against	Against
14	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against

21-Feb-24 62 of 140

15	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
16	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
17	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
18	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
19	Authority to Issue Shares w/o Preemptive Rights (American	Management	For	Against	Against
20	Authority to Issue Shares and Convertible Debt w/	Management	For	Against	Against
21	Authority to Issue Shares and Convertible Debt w/o	Management	For	Against	Against
22	Authority to Issue Shares and Convertible Debt Through	Management	For	Against	Against
23	Greenshoe	Management	For	Against	Against
24	Global Ceiling on Capital Increases and Debt Issuances	Management	For	For	For
25	Authority to Increase Capital Through Capitalisations	Management	For	For	For
26	Authority to Grant Stock Options	Management	For	Against	Against
27	Authority to Issue Performance Shares	Management	For	Against	Against
28	Global Ceiling on Capital Increases for Equity	Management	For	For	For
29	Employee Stock Purchase Plan	Management	Against	For	Against

21-Feb-24 63 of 140

TERUMO CORPORATION

ISIN JP3546800008 Meeting Date 27-Jun-23

Country Japan

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1	Allocation of Profits/Dividends	Management	For	For	For
2	Amendments to Articles	Management	For	For	For
3.1	Elect Toshiaki Takagi	Management	For	For	For
3.2	Elect Shinjiro Sato	Management	For	For	For
3.3	Elect Shoji Hatano	Management	For	For	For
3.4	Elect Kazunori Hirose	Management	For	For	For
3.5	Elect Norimasa Kunimoto	Management	For	For	For
3.6	Elect Yukiko Kuroda @ Yukiko Matsumoto	Management	For	For	For
3.7	Elect Hidenori Nishi	Management	For	For	For
3.8	Elect Keiya Ozawa	Management	For	For	For
4.1	Elect Takanori Shibazaki	Management	For	Against	Against
4.2	Elect Masaichi Nakamura	Management	For	For	For
4.3	Elect Soichiro Uno	Management	For	For	For
5	Elect Koichi Sakaguchi as Alternate Audit Committee	Management	For	For	For

NIPPON SHINYAKU CO. LTD.

ISIN JP3717600005 Meeting Date 29-Jun-23

21-Feb-24 64 of 140

Country Japan

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Allocation of Profits/Dividends	Management	For	For	For
2.1	Elect Shigenobu Maekawa	Management	For	For	For
2.2	Elect Toru Nakai	Management	For	For	For
2.3	Elect Shozo Sano	Management	For	For	For
2.4	Elect Takashi Takaya	Management	For	For	For
2.5	Elect Takanori Edamitsu	Management	For	For	For
2.6	Elect Kazuchika Takagaki	Management	For	For	For
2.7	Elect Hitoshi Ishizawa	Management	For	For	For
2.8	Elect Hitomi Kimura	Management	For	For	For
2.9	Elect Miyuki Sakurai	Management	For	For	For
2.10	Elect Yoshinao Wada	Management	For	For	For
2.11	Elect Yukari Kobayashi	Management	For	For	For
2.12	Elect Mayumi Nishi	Management	For	For	For
3.1	Elect Hirotsugu Ito	Management	For	Against	Against
3.2	Elect Hiroharu Hara	Management	For	For	For

REPLIMUNE GROUP INC

ISIN	US76029N1063	Meeting Date	06-Sep-23	
Country	United States			

21-Feb-24 65 of 140

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.1	Elect Paolo Pucci	Management	For	Withhold	Against
1.2	Elect Veleka Peeples-Dyer	Management	For	For	For
2.	Ratification of Auditor	Management	For	For	For

NOVARTIS AG

 ISIN
 CH0012005267
 Meeting Date
 15-Sep-23

 Country
 Switzerland

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1	Dividend in Kind to Effect Spin-Off of Sandoz Group AG	Management	For	For	For
2	Amendment to Par Value	Management	For	For	For
3	Additional or Amended Proposals	Management		Against	N/A

MEDTRONIC PLC

ISIN IE00BTN1Y115 Meeting Date 19-Oct-23
Country Ireland

21-Feb-24 66 of 140

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1a.	Elect Craig Arnold	Management	For	For	For
1b.	Elect Scott C. Donnelly	Management	For	For	For
1c.	Elect Lidia L. Fonseca	Management	For	For	For
1d.	Elect Andrea J. Goldsmith	Management	For	For	For
1e.	Elect Randall J. Hogan, III	Management	For	For	For
1f.	Elect Gregory P. Lewis	Management	For	For	For
1g.	Elect Kevin E. Lofton	Management	For	For	For
1h.	Elect Geoffrey Straub Martha	Management	For	For	For
1i.	Elect Elizabeth G. Nabel	Management	For	For	For
1j.	Elect Denise M. O'Leary	Management	For	For	For
1k.	Elect Kendall J. Powell	Management	For	Against	Against
2.	Appointment of Auditor and Authority to Set Fees	Management	For	For	For
3.	Advisory Vote on Executive Compensation	Management	For	For	For
4.	Approval of the 2024 Employee Stock Purchase Plan	Management	For	For	For
5.	Authority to Issue Shares w/ Preemptive Rights	Management	For	For	For
6.	Authority to Issue Shares w/o Preemptive Rights	Management	For	For	For
7.	Authority to Repurchase Shares	Management	For	For	For

MIRATI THERAPEUTICS INC

ISIN	US60468T1051	Meeting Date	13-Dec-23
Country	United States		

21-Feb-24 67 of 140

Proposal					For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1.	Bristol-Myers Transaction	Management	For	For	For
2.	Advisory Vote on Golden Parachutes	Management	For	Against	Against
3.	Right to Adjourn Meeting	Management	For	For	For

VIATRIS INC

ISIN US92556V1061 Meeting Date 15-Dec-23
Country United States

Proposal				V (For/Agains
Number	Proposal	Proponent	Mgmt Rec	Vote	Mgmt
1A.	Elect W. Don Cornwell	Management	For	For	For
1B.	Elect JoEllen Lyons Dillon	Management	For	Against	Against
1C.	Elect Elisha W. Finney	Management	For	For	For
1D.	Elect Leo Groothuis	Management	For	For	For
1E.	Elect Melina E. Higgins	Management	For	For	For
1F.	Elect James M. Kilts	Management	For	For	For
1G.	Elect Harry A. Korman	Management	For	For	For
1H.	Elect Rajiv Malik	Management	For	For	For
11.	Elect Richard A. Mark	Management	For	For	For
1J.	Elect Mark W. Parrish	Management	For	For	For

21-Feb-24 68 of 140

1K.	Elect Scott A. Smith	Management	For	For	For
2.	Advisory Vote on Executive Compensation	Management	For	For	For
3.	Ratification of Auditor	Management	For	For	For
4.	Amendment to the Certificate of Incorporation Regarding	Management	For	Against	Against
5.	Amendment to Articles Regarding Officer Exculpation	Management	For	Against	Against

CELLECTIS

 ISIN
 FR0010425595
 Meeting Date
 22-Dec-23

 Country
 France

Proposal Number	Proposal	Proponent	Mgmt Rec	Vote	For/Agains Mgmt
1	Creation of a New Category of Preference Shares (A	Management	For	For	For
2	Issuance of Shares w/o Preemptive Rights (AstraZeneca	Management	For	For	For
3	Creation of a New Category of Preference Shares (B	Management	For	For	For
4	Authority to Issue Preference Shares (AstraZeneca	Management	For	For	For
5	Suppression of Preemptive rights (AstraZeneca Holdings	Management	For	For	For
6	Employee Stock Purchase Plan	Management	Against	For	Against

21-Feb-24 69 of 140

/	Elect AstraZeneca Holdings B.V. (Marc Dunoyer)	Management	For	Against	Against
8	Elect AstraZeneca Holdings B.V. (Tyrell J. Rivers)	Management	For	For	For

21-Feb-24 70 of 140

ŧŧ

21-Feb-24 71 of 140

t

21-Feb-24 72 of 140

t

21-Feb-24 73 of 140

Mix

ŧŧ

21-Feb-24 74 of 140

ŧ

21-Feb-24 75 of 140

it

21-Feb-24 76 of 140

ŧ

21-Feb-24 77 of 140

t

Annual

21-Feb-24 78 of 140

ŧ

21-Feb-24 79 of 140

ŧ٤

21-Feb-24 80 of 140

ŧ٤

21-Feb-24 81 of 140

ŧ٤

21-Feb-24 82 of 140

Mix

st

21-Feb-24 83 of 140

51

21-Feb-24 84 of 140

it

21-Feb-24 85 of 140

ŧ٤

21-Feb-24 86 of 140

ŧ

21-Feb-24 87 of 140

t

21-Feb-24 88 of 140

ŧ٤

Annual

ŧt

21-Feb-24 89 of 140

t

21-Feb-24 90 of 140

۶t

21-Feb-24 91 of 140

ŧ

21-Feb-24 92 of 140

21-Feb-24 93 of 140

ŧ

Annual

۶t

it

21-Feb-24 95 of 140

ŧŧ

21-Feb-24 96 of 140

t

21-Feb-24 97 of 140

Mix

ŧ

21-Feb-24 98 of 140

21-Feb-24 99 of 140

۶t

21-Feb-24 100 of 140

ŧ

21-Feb-24 101 of 140

ŧŧ

Annual

21-Feb-24 102 of 140

it

Annual

st

ŧ

21-Feb-24 104 of 140

Mix

t

21-Feb-24 105 of 140

21-Feb-24 106 of 140

t

21-Feb-24 107 of 140

Mix

it

21-Feb-24 108 of 140

21-Feb-24 109 of 140

t

Mix

ŧ

21-Feb-24 111 of 140

ŧ

21-Feb-24 112 of 140

t

Annual

21-Feb-24 113 of 140

ŧŧ

Mix

ŧ٤

21-Feb-24 114 of 140

21-Feb-24 115 of 140

t

21-Feb-24 116 of 140

ŧ

21-Feb-24 117 of 140

51

21-Feb-24 118 of 140

21-Feb-24 119 of 140

ŧ

Annual

t

ŧ

21-Feb-24 121 of 140

ŧ

Annual

21-Feb-24 122 of 140

ŧŧ

Annual

:1

21-Feb-24 123 of 140

t

Annual

t

t

21-Feb-24 125 of 140

Mix

21-Feb-24 126 of 140

t

21-Feb-24 127 of 140

21-Feb-24 128 of 140

Annual

t

Annual

21-Feb-24 129 of 140

ŧ٤

Mix

:1

21-Feb-24

21-Feb-24 131 of 140

Mix

ŧt

21-Feb-24 132 of 140

21-Feb-24 133 of 140

Annual

t

Annual

21-Feb-24 134 of 140

ŧ

Annual

21-Feb-24 135 of 140

it

Special

t

Annual

Special

21-Feb-24 137 of 140

it

Annual

ŧŧ

21-Feb-24 138 of 140

Mix

ŧ٤

21-Feb-24 139 of 140

21-Feb-24 140 of 140